

METLIFE INC  
Form 10-Q  
November 05, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 10-Q  
(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT  
OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2015

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT  
OF 1934

FOR THE TRANSITION PERIOD FROM TO

Commission file number: 001-15787

MetLife, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of  
incorporation or organization)

13-4075851

(I.R.S. Employer  
Identification No.)

200 Park Avenue, New York, N.Y.

(Address of principal executive offices)

(212) 578-9500

(Registrant's telephone number, including area code)

10166-0188

(Zip Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company)

Smaller reporting  
company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

At October 30, 2015, 1,111,626,481 shares of the registrant's common stock, \$0.01 par value per share, were outstanding.

## Table of Contents

	Page
<u>Part I — Financial Information</u>	
Item 1.	3
Financial Statements (at September 30, 2015 (Unaudited) and December 31, 2014 and for the Three Months and Nine Months Ended September 30, 2015 and 2014 (Unaudited))	3
<u>Interim Condensed Consolidated Balance Sheets</u>	4
<u>Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</u>	5
<u>Interim Condensed Consolidated Statements of Equity</u>	6
<u>Interim Condensed Consolidated Statements of Cash Flows</u>	7
<u>Notes to the Interim Condensed Consolidated Financial Statements:</u>	
<u>Note 1 — Business, Basis of Presentation and Summary of Significant Accounting Policies</u>	8
<u>Note 2 — Segment Information</u>	17
<u>Note 3 — Insurance</u>	18
<u>Note 4 — Closed Block</u>	20
<u>Note 5 — Investments</u>	36
<u>Note 6 — Derivatives</u>	52
<u>Note 7 — Fair Value</u>	81
<u>Note 8 — Long-term Debt</u>	81
<u>Note 9 — Equity</u>	87
<u>Note 10 — Other Expenses</u>	87
<u>Note 11 — Employee Benefit Plans</u>	88
<u>Note 12 — Income Tax</u>	89
<u>Note 13 — Earnings Per Common Share</u>	90
<u>Note 14 — Contingencies, Commitments and Guarantees</u>	97
<u>Note 15 — Subsequent Events</u>	98
Item 2.	98
<u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	180
Item 3.	181
<u>Quantitative and Qualitative Disclosures About Market Risk</u>	
Item 4.	181
<u>Controls and Procedures</u>	
<u>Part II — Other Information</u>	
Item 1.	182
<u>Legal Proceedings</u>	
Item 1A.	185
<u>Risk Factors</u>	
Item 2.	186
<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	
Item 5.	188
<u>Other Information</u>	
Item 6.	189
<u>Exhibits</u>	
<u>Signatures</u>	190
<u>Exhibit Index</u>	E - 1

Table of Contents

As used in this Form 10 Q, “MetLife,” the “Company,” “we,” “our” and “us” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates.

Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10 Q, including Management’s Discussion and Analysis of Financial Condition and Results of Operations, may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements give expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning, or are tied to future periods, in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective services or products, future performance or results of current and anticipated services or products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, trends in operations and financial results.

Any or all forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining the actual future results of MetLife, Inc., its subsidiaries and affiliates. These statements are based on current expectations and the current economic environment. They involve a number of risks and uncertainties that are difficult to predict. These statements are not guarantees of future performance. Actual results could differ materially from those expressed or implied in the forward-looking statements. Risks, uncertainties, and other factors that might cause such differences include the risks, uncertainties and other factors identified in MetLife, Inc.’s filings with the U.S. Securities and Exchange Commission. These factors include: (1) difficult conditions in the global capital markets; (2) increased volatility and disruption of the capital and credit markets, which may affect our ability to meet liquidity needs and access capital, including through our credit facilities, generate fee income and market-related revenue and finance statutory reserve requirements and may require us to pledge collateral or make payments related to declines in value of specified assets, including assets supporting risks ceded to certain of our captive reinsurers or hedging arrangements associated with those risks; (3) exposure to financial and capital market risks, including as a result of the disruption in Europe and possible withdrawal of one or more countries from the Euro zone; (4) impact of comprehensive financial services regulation reform on us, as a non-bank systemically important financial institution, or otherwise; (5) numerous rulemaking initiatives required or permitted by the Dodd-Frank Wall Street Reform and Consumer Protection Act which may impact how we conduct our business, including those compelling the liquidation of certain financial institutions; (6) regulatory, legislative or tax changes relating to our insurance, international, or other operations that may affect the cost of, or demand for, our products or services, or increase the cost or administrative burdens of providing benefits to employees; (7) adverse results or other consequences from litigation, arbitration or regulatory investigations; (8) potential liquidity and other risks resulting from our participation in a securities lending program and other transactions; (9) investment losses and defaults, and changes to investment valuations; (10) changes in assumptions related to investment valuations, deferred policy acquisition costs, deferred sales inducements, value of business acquired or goodwill; (11) impairments of goodwill and realized losses or market value impairments to illiquid assets; (12) defaults on our mortgage loans; (13) the defaults or deteriorating credit of other financial institutions that could adversely affect us; (14) economic, political, legal, currency and other risks relating to our international operations, including with respect to fluctuations of exchange rates; (15) downgrades in our claims paying ability, financial strength or credit ratings; (16) a deterioration in the experience of the “closed block” established in connection with the reorganization of Metropolitan Life Insurance Company; (17) availability and effectiveness of reinsurance or indemnification arrangements, as well as any default or failure of counterparties to perform; (18) differences between actual claims experience and underwriting and reserving assumptions; (19) ineffectiveness of risk management policies and procedures; (20) catastrophe losses; (21) increasing cost and limited market capacity for statutory life insurance reserve financings; (22) heightened competition, including with respect to pricing, entry of new competitors, consolidation of distributors, the development of new products by new and existing competitors, and for personnel; (23) exposure to losses related to variable annuity guarantee benefits, including from significant and sustained downturns or extreme volatility in equity markets, reduced interest rates,

unanticipated policyholder behavior, mortality or longevity, and the adjustment for nonperformance risk; (24) our ability to address difficulties, unforeseen liabilities, asset impairments, or rating agency actions arising from business acquisitions and integrating and managing the growth of such acquired businesses, or arising from dispositions of businesses or legal entity reorganizations; (25) regulatory and other restrictions affecting MetLife, Inc.'s ability to pay dividends and repurchase common stock; (26) MetLife, Inc.'s primary reliance, as a holding company, on dividends from its subsidiaries to meet debt payment obligations and the applicable regulatory restrictions on the ability of the subsidiaries to pay such dividends; (27) the possibility that MetLife, Inc.'s Board of Directors may influence the outcome of stockholder votes through the voting provisions of the MetLife Policyholder Trust; (28) changes in accounting standards, practices and/or policies; (29) increased expenses relating to pension and postretirement benefit plans, as well as health care and other employee benefits; (30) inability to protect our intellectual property rights or claims of infringement of the intellectual property rights of others; (31) inability to attract and retain sales representatives; (32) provisions of laws and our incorporation documents may delay, deter or prevent takeovers and corporate combinations involving MetLife; (33) the effects of business disruption or economic contraction due to disasters such as terrorist attacks, cyberattacks, other hostilities, or natural catastrophes, including any related impact on the value of our investment portfolio, our disaster recovery systems, cyber- or other information security systems and management continuity planning; (34) the effectiveness of our programs and practices in avoiding giving our associates incentives to take excessive risks; and (35) other risks and uncertainties described from time to time in MetLife, Inc.'s filings with the U.S. Securities and Exchange Commission.

MetLife, Inc. does not undertake any obligation to publicly correct or update any forward-looking statement if MetLife, Inc. later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures MetLife, Inc. makes on related subjects in reports to the U.S. Securities and Exchange Commission.

#### Corporate Information

We announce financial and other information about MetLife to our investors through the MetLife Investor Relations web page at [www.metlife.com](http://www.metlife.com), as well as U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. MetLife encourages investors to visit the Investor Relations web page from time to time, as information is updated and new information is posted. The information found on our website is not incorporated by reference into this Quarterly Report on Form 10-Q or in any other report or document we file with the U.S. Securities and Exchange Commission, and any references to our website are intended to be inactive textual references only.

#### Note Regarding Reliance on Statements in Our Contracts

See "Exhibit Index — Note Regarding Reliance on Statements in Our Contracts" for information regarding agreements included as exhibits to this Quarterly Report on Form 10-Q.

Table of Contents

## Part I — Financial Information

## Item 1. Financial Statements

MetLife, Inc.

Interim Condensed Consolidated Balance Sheets

September 30, 2015 (Unaudited) and December 31, 2014

(In millions, except share and per share data)

	September 30, 2015	December 31, 2014
Assets		
Investments:		
Fixed maturity securities available-for-sale, at estimated fair value (amortized cost: \$329,203 and \$334,780, respectively; includes \$4,293 and \$4,266, respectively, relating to variable interest entities)	\$ 351,578	\$ 365,425
Equity securities available-for-sale, at estimated fair value (cost: \$3,096 and \$3,076, respectively)	3,399	3,631
Fair value option and trading securities, at estimated fair value (includes \$696 and \$704, respectively, of actively traded securities; and \$14 and \$60, respectively, relating to variable interest entities)	15,361	16,689
Mortgage loans (net of valuation allowances of \$311 and \$305, respectively; includes \$290 and \$280, respectively, at estimated fair value, relating to variable interest entities; includes \$315 and \$308, respectively, under the fair value option)	63,553	60,118
Policy loans (includes \$4 and \$3, respectively, relating to variable interest entities)	11,549	11,618
Real estate and real estate joint ventures (includes \$0 and \$8, respectively, relating to variable interest entities; includes \$905 and \$172, respectively, of real estate held-for-sale)	9,923	10,525
Other limited partnership interests (includes \$27 and \$34, respectively, relating to variable interest entities)	7,901	8,085
Short-term investments, principally at estimated fair value (includes \$26 and \$20, respectively, relating to variable interest entities)	14,957	8,621
Other invested assets, principally at estimated fair value (includes \$43 and \$56, respectively, relating to variable interest entities)	23,356	21,283
Total investments	501,577	505,995
Cash and cash equivalents, principally at estimated fair value (includes \$48 and \$57, respectively, relating to variable interest entities)	10,216	10,808
Accrued investment income (includes \$26 and \$21, respectively, relating to variable interest entities)	4,187	4,120
Premiums, reinsurance and other receivables (includes \$21 and \$21, respectively, relating to variable interest entities)	25,808	22,244
Deferred policy acquisition costs and value of business acquired (includes \$230 and \$235, respectively, relating to variable interest entities)	23,996	24,442
Goodwill	9,546	9,872
Other assets (includes \$146 and \$134, respectively, relating to variable interest entities)	7,881	7,862
Separate account assets (includes \$1,056 and \$1,128, respectively, relating to variable interest entities)	299,249	316,994
Total assets	\$ 882,460	\$ 902,337
Liabilities and Equity		
Liabilities		

Edgar Filing: METLIFE INC - Form 10-Q

Future policy benefits (includes \$670 and \$579, respectively, relating to variable interest entities)	\$ 190,754	\$ 189,586
Policyholder account balances (includes \$21 and \$33, respectively, relating to variable interest entities)	202,291	209,294
Other policy-related balances (includes \$225 and \$198, respectively, relating to variable interest entities)	14,521	14,422
Policyholder dividends payable	716	684
Policyholder dividend obligation	2,309	3,155
Payables for collateral under securities loaned and other transactions	37,991	35,326
Short-term debt	100	100
Long-term debt (includes \$162 and \$151, respectively, at estimated fair value, relating to variable interest entities)	16,755	16,286
Collateral financing arrangements	4,152	4,196
Junior subordinated debt securities	3,194	3,193
Current income tax payable	21	184
Deferred income tax liability	11,363	11,821
Other liabilities (includes \$71 and \$80, respectively, relating to variable interest entities)	27,977	24,437
Separate account liabilities (includes \$1,056 and \$1,128, respectively, relating to variable interest entities)	299,249	316,994
Total liabilities	811,393	829,678
Contingencies, Commitments and Guarantees (Note 14)		
Redeemable noncontrolling interests in partially-owned consolidated subsidiaries	79	99
Equity		
MetLife, Inc.'s stockholders' equity:		
Preferred stock, par value \$0.01 per share; \$2,100 aggregate liquidation preference	—	1
Common stock, par value \$0.01 per share; 3,000,000,000 shares authorized; 1,159,310,431 and 1,153,998,144 shares issued, respectively; 1,114,764,365 and 1,131,927,894 shares outstanding, respectively	12	12
Additional paid-in capital	30,726	30,543
Retained earnings	35,153	32,020
Treasury stock, at cost; 44,546,066 and 22,070,250 shares, respectively	(2,279 )	(1,172 )
Accumulated other comprehensive income (loss)	6,891	10,649
Total MetLife, Inc.'s stockholders' equity	70,503	72,053
Noncontrolling interests	485	507
Total equity	70,988	72,560
Total liabilities and equity	\$ 882,460	\$ 902,337
See accompanying notes to the interim condensed consolidated financial statements.		

Table of Contents

MetLife, Inc.

Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

For the Three Months and Nine Months Ended September 30, 2015 and 2014 (Unaudited)

(In millions, except per share data)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2015	2014	2015	2014
Revenues				
Premiums	\$10,375	\$9,703	\$28,940	\$28,795
Universal life and investment-type product policy fees	2,346	2,628	7,174	7,507
Net investment income	3,959	5,410	14,367	15,704
Other revenues	484	518	1,497	1,486
Net investment gains (losses):				
Other-than-temporary impairments on fixed maturity securities	(43 )	(17 )	(51 )	(40 )
Other-than-temporary impairments on fixed maturity securities transferred to other comprehensive income (loss)	16	(14 )	4	(16 )
Other net investment gains (losses)	409	140	582	(371 )
Total net investment gains (losses)	382	109	535	(427 )
Net derivative gains (losses)	485	478	394	1,132
Total revenues	18,031	18,846	52,907	54,197
Expenses				
Policyholder benefits and claims	10,334	9,512	28,943	28,824
Interest credited to policyholder account balances	647	1,817	3,940	4,995
Policyholder dividends	354	347	1,024	1,047
Other expenses	4,533	4,218	12,665	12,603
Total expenses	15,868	15,894	46,572	47,469
Income (loss) from continuing operations before provision for income tax	2,163	2,952	6,335	6,728
Provision for income tax expense (benefit)	965	858	1,855	1,916
Income (loss) from continuing operations, net of income tax	1,198	2,094	4,480	4,812
Income (loss) from discontinued operations, net of income tax	—	—	—	(3 )
Net income (loss)	1,198	2,094	4,480	4,809
Less: Net income (loss) attributable to noncontrolling interests	(5 )	—	4	21
Net income (loss) attributable to MetLife, Inc.	1,203	2,094	4,476	4,788
Less: Preferred stock dividends	6	30	67	91
Preferred stock repurchase premium	—	—	42	—
Net income (loss) available to MetLife, Inc.'s common shareholders	\$1,197	\$2,064	\$4,367	\$4,697
Comprehensive income (loss)	\$1,653	\$1,972	\$760	\$10,682
Less: Comprehensive income (loss) attributable to noncontrolling interests, net of income tax	2	(56 )	42	6
Comprehensive income (loss) attributable to MetLife, Inc.	\$1,651	\$2,028	\$718	\$10,676
Income (loss) from continuing operations, net of income tax, available to MetLife, Inc.'s common shareholders per common share:				
Basic	\$1.07	\$1.83	\$3.90	\$4.17
Diluted	\$1.06	\$1.81	\$3.86	\$4.12
Net income (loss) available to MetLife, Inc.'s common shareholders per common share:				
Basic	\$1.07	\$1.83	\$3.90	\$4.17

Edgar Filing: METLIFE INC - Form 10-Q

Diluted	\$1.06	\$1.81	\$3.86	\$4.12
Cash dividends declared per common share	\$0.375	\$0.350	\$1.100	\$0.975

See accompanying notes to the interim condensed consolidated financial statements.



Table of Contents

MetLife, Inc.

Interim Condensed Consolidated Statements of Equity

For the Nine Months Ended September 30, 2015 and 2014 (Unaudited)

(In millions)

	Preferred Stock	Common Stock	Additional Paid-in Capital	Retained Earnings	Treasury Stock at Cost	Accumulated Other Comprehensive Income (Loss)	Total MetLife, Inc.'s Stockholders' Equity	Noncontrolling Interests (1)	Total Equity
Balance at December 31, 2014	\$ 1	\$ 12	\$ 30,543	\$ 32,020	\$ (1,172)	\$ 10,649	\$ 72,053	\$ 507	\$ 72,560
Repurchase of preferred stock	(1 )		(1,459 )				(1,460 )		(1,460 )
Preferred stock repurchase premium				(42 )			(42 )		(42 )
Preferred stock issuance	—		1,483				1,483		1,483
Treasury stock acquired in connection with share repurchases					(1,107 )		(1,107 )		(1,107 )
Stock-based compensation			159				159		159
Dividends on preferred stock				(67 )			(67 )		(67 )
Dividends on common stock				(1,234 )			(1,234 )		(1,234 )
Change in equity of noncontrolling interests							—	(64 )	(64 )
Net income (loss)				4,476			4,476	4	4,480
Other comprehensive income (loss), net of income tax						(3,758 )	(3,758 )	38	(3,720 )
Balance at September 30, 2015	\$ —	\$ 12	\$ 30,726	\$ 35,153	\$ (2,279)	\$ 6,891	\$ 70,503	\$ 485	\$ 70,988
	Preferred Stock	Common Stock	Additional Paid-in Capital	Retained Earnings	Treasury Stock at Cost	Accumulated Other Comprehensive Income (Loss)	Total MetLife, Inc.'s Stockholders' Equity	Noncontrolling Interests (1)	Total Equity
Balance at December 31, 2013	\$ 1	\$ 11	\$ 29,277	\$ 27,332	\$ (172)	\$ 5,104	\$ 61,553	\$ 543	\$ 62,096
Treasury stock acquired in connection with share repurchases					(443 )		(443 )		(443 )
Stock-based compensation			211				211		211

Edgar Filing: METLIFE INC - Form 10-Q

Dividends on preferred stock				(91 )			(91 )		(91 )
Dividends on common stock				(1,101 )			(1,101 )		(1,101 )
Change in equity of noncontrolling interests							—	(55 )	(55 )
Net income (loss)				4,788			4,788	21	4,809
Other comprehensive income (loss), net of income tax					5,888		5,888	(15 )	5,873
Balance at September 30, 2014	\$ 1	\$ 11	\$ 29,488	\$ 30,928	\$ (615 )	\$ 10,992	\$ 70,805	\$ 494	\$ 71,299

(1) Net income (loss) attributable to noncontrolling interests excludes losses of redeemable noncontrolling interests in partially-owned consolidated subsidiaries of less than \$1 million at both September 30, 2015 and 2014. See accompanying notes to the interim condensed consolidated financial statements.

Table of Contents

MetLife, Inc.

Interim Condensed Consolidated Statements of Cash Flows

For the Nine Months Ended September 30, 2015 and 2014 (Unaudited)

(In millions)

	Nine Months Ended September 30,	
	2015	2014
Net cash provided by (used in) operating activities	\$9,527	\$10,950
Cash flows from investing activities		
Sales, maturities and repayments of:		
Fixed maturity securities	109,308	85,187
Equity securities	478	455
Mortgage loans	9,775	10,917
Real estate and real estate joint ventures	1,644	532
Other limited partnership interests	859	555
Purchases of:		
Fixed maturity securities	(105,128)	(94,085)
Equity securities	(431)	(455)
Mortgage loans	(13,814)	(11,772)
Real estate and real estate joint ventures	(977)	(1,382)
Other limited partnership interests	(935)	(1,338)
Cash received in connection with freestanding derivatives	2,376	977
Cash paid in connection with freestanding derivatives	(2,887)	(2,530)
Cash received under repurchase agreements (Note 5)	199	—
Cash paid under reverse repurchase agreements (Note 5)	(199)	—
Sales of businesses, net of cash and cash equivalents disposed of \$0 and \$262, respectively	—	452
Purchases of investments in insurance joint ventures	—	(277)
Net change in policy loans	10	(19)
Net change in short-term investments	(6,644)	1,496
Net change in other invested assets	(350)	(251)
Other, net	(191)	(131)
Net cash provided by (used in) investing activities	(6,907)	(11,669)
Cash flows from financing activities		
Policyholder account balances:		
Deposits	69,383	73,855
Withdrawals	(72,940)	(71,301)
Net change in payables for collateral under securities loaned and other transactions	2,664	3,481
Net change in short-term debt	—	(75)
Long-term debt issued	1,578	1,000
Long-term debt repaid	(1,078)	(2,802)
Collateral financing arrangements repaid	(44)	—
Cash received (paid) in connection with collateral financing arrangements	6	—
Treasury stock acquired in connection with share repurchases	(1,107)	(443)
Preferred stock issued, net of issuance costs	1,483	—
Repurchase of preferred stock	(1,460)	—
Preferred stock repurchase premium	(42)	—
Dividends on preferred stock	(67)	(91)

Edgar Filing: METLIFE INC - Form 10-Q

Dividends on common stock	(1,234	) (1,101	)
Other, net	6	(546	)
Net cash provided by (used in) financing activities	(2,852	) 1,977	
Effect of change in foreign currency exchange rates on cash and cash equivalents balances	(360	) (60	)
Change in cash and cash equivalents	(592	) 1,198	
Cash and cash equivalents, beginning of period	10,808	7,585	
Cash and cash equivalents, end of period	\$10,216	\$8,783	
Supplemental disclosures of cash flow information			
Net cash paid (received) for:			
Interest	\$836	\$841	
Income tax	\$904	\$413	
Non-cash transactions:			
Fixed maturity securities received in connection with pension closeout transactions	\$903	\$—	
Deconsolidation of MetLife Core Property Fund:			
Reduction of redeemable noncontrolling interests	\$—	\$774	
Reduction of long-term debt	\$—	\$413	
Reduction of real estate and real estate joint ventures	\$—	\$1,132	
See accompanying notes to the interim condensed consolidated financial statements.			

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

1. Business, Basis of Presentation and Summary of Significant Accounting Policies

Business

“MetLife” and the “Company” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. MetLife is a global provider of life insurance, annuities, employee benefits and asset management. MetLife is organized into six segments: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; and Latin America (collectively, the “Americas”); Asia; and Europe, the Middle East and Africa (“EMEA”).

Basis of Presentation

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported in the interim condensed consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from estimates.

The accompanying interim condensed consolidated financial statements include the accounts of MetLife, Inc. and its subsidiaries, as well as partnerships and joint ventures in which the Company has control, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions have been eliminated.

Certain international subsidiaries have a fiscal year cutoff of November 30th. Accordingly, the Company’s interim condensed consolidated financial statements reflect the assets and liabilities of such subsidiaries as of August 31, 2015 and November 30, 2014 and the operating results of such subsidiaries for the three months and nine months ended August 31, 2015 and 2014.

The Company uses the equity method of accounting for equity securities when it has significant influence or at least 20% interest and for real estate joint ventures and other limited partnership interests (“investees”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations, but does not have a controlling financial interest. The Company generally recognizes its share of the investee’s earnings on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period. The Company uses the cost method of accounting for investments in which it has virtually no influence over the investee’s operations.

Certain amounts in the prior year periods’ interim condensed consolidated financial statements and related footnotes thereto have been reclassified to conform with the 2015 presentation as discussed throughout the Notes to the Interim Condensed Consolidated Financial Statements.

The accompanying interim condensed consolidated financial statements are unaudited and reflect all adjustments (including normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Interim results are not necessarily indicative of full year performance. The December 31, 2014 consolidated balance sheet data was derived from audited consolidated financial statements included in MetLife, Inc.’s Annual Report on Form 10 K for the year ended December 31, 2014, as revised by MetLife, Inc.’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (“SEC”) on May 21, 2015 (as revised, the “2014 Annual Report”), which include all disclosures required by GAAP. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company included in the 2014 Annual Report.

Adoption of New Accounting Pronouncements

Effective January 1, 2015, the Company adopted guidance requiring repurchase-to-maturity transactions and repurchase financing arrangements to be accounted for as secured borrowings and providing for enhanced disclosures, including the nature of collateral pledged and the time to maturity. Certain interim period disclosures for repurchase agreements and securities lending transactions were not required until the second quarter of 2015. The Company has provided these enhanced disclosures in Note 5. The adoption of this new guidance did not have a material impact on

the Company's consolidated financial statements.

7

---

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)

Future Adoption of New Accounting Pronouncements

In May 2015, the Financial Accounting Standards Board (“FASB”) issued new guidance on short-duration insurance contracts (Accounting Standards Update (“ASU”) 2015-09, Financial Services - Insurance (Topic 944): Disclosures about Short-Duration Contracts). The amendments in this new guidance are effective for annual periods beginning after December 15, 2015, and interim periods within annual periods beginning after December 15, 2016. The new guidance should be applied retrospectively by providing comparative disclosures for each period presented, except for those requirements that apply only to the current period. The new guidance requires insurance entities to provide users of financial statements with more transparent information about initial claim estimates and subsequent adjustments to these estimates, including information on: (i) reconciling from the claim development table to the balance sheet liability, (ii) methodologies and judgments in estimating claims, and (iii) the timing, and frequency of claims. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

In May 2015, the FASB issued new guidance on fair value measurement (ASU 2015 07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent)), effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years and which should be applied retrospectively to all periods presented. Earlier application is permitted. The new amendments in this ASU remove the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value (“NAV”) per share practical expedient. In addition, the amendments remove the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

In April 2015, the FASB issued new guidance on accounting for fees paid in a cloud computing arrangement (ASU 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement), effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption of the new guidance is permitted and an entity can elect to adopt the guidance either: (1) prospectively to all arrangements entered into or materially modified after the effective date; or (2) retrospectively. The new guidance provides that all software licenses included in cloud computing arrangements be accounted for consistent with other licenses of intangible assets. However, if a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract, the accounting for which did not change. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

In February 2015, the FASB issued certain amendments to the consolidation analysis to improve consolidation guidance for legal entities (ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis), effective for fiscal years beginning after December 15, 2015 and interim periods within those years and early adoption is permitted. The new standard is intended to improve targeted areas of the consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures. The amendments in this ASU affect the consolidation evaluation for reporting organizations. In addition, the amendments in this ASU simplify and improve current GAAP by reducing the number of consolidation models. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

In May 2014, the FASB issued a comprehensive new revenue recognition standard (ASU 2014-09, Revenue from Contracts with Customers (Topic 606)), effective for fiscal years beginning after December 15, 2016 and interim periods within those years and should be applied retrospectively. In July 2015, the FASB voted to defer the effective date of this ASU by one year, effective for fiscal years beginning after December 15, 2017. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The new guidance will supersede nearly all existing revenue recognition guidance under GAAP; however, it will not impact the accounting for insurance contracts, leases, financial instruments and guarantees. For those contracts that are impacted by the new guidance, the guidance will require an entity to recognize

revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

## 2. Segment Information

MetLife is organized into six segments, reflecting three broad geographic regions: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; and Latin America (collectively, the “Americas”); Asia; and EMEA. In addition, the Company reports certain of its results of operations in Corporate & Other.



Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

2. Segment Information (continued)

In the first quarter of 2015, the Company implemented certain segment reporting changes related to the (i) measurement of segment operating earnings, which included revising the Company's capital allocation methodology, and (ii) the realignment of consumer direct business. These changes were applied retrospectively and did not have an impact on total consolidated operating earnings or net income.

Americas

The Americas consists of the following segments:

Retail

The Retail segment offers a broad range of protection products and services and a variety of annuities to individuals and employees of corporations and other institutions, and is organized into two businesses: Life & Other and Annuities. Life & Other insurance products and services include variable life, universal life, term life and whole life products. Additionally, through broker-dealer affiliates, the Company offers a full range of mutual funds and other securities products. Life & Other products and services also include individual disability income products and personal lines property & casualty insurance, including private passenger automobile, homeowners and personal excess liability insurance. Annuities includes a variety of variable and fixed annuities which provide for both asset accumulation and asset distribution needs.

Group, Voluntary & Worksite Benefits

The Group, Voluntary & Worksite Benefits segment offers a broad range of protection products and services to individuals and corporations, as well as other institutions and their respective employees. Group, Voluntary & Worksite Benefits insurance products and services include life, dental, group short- and long-term disability and accidental death and dismemberment ("AD&D") coverages. In addition, the Group, Voluntary & Worksite Benefits segment offers property & casualty insurance, including private passenger automobile, homeowners and personal excess liability, which is offered to employees on a voluntary basis, long-term care, critical illness and accident & health coverages, as well as prepaid legal plans.

Corporate Benefit Funding

The Corporate Benefit Funding segment offers a broad range of annuity and investment products, including guaranteed interest products and other stable value products, income annuities and separate account contracts for the investment management of defined benefit and defined contribution plan assets. This segment also includes structured settlements and certain products to fund postretirement benefits and company-, bank- or trust-owned life insurance used to finance non-qualified benefit programs for executives.

Latin America

The Latin America segment offers a broad range of products to both individuals and corporations, as well as other institutions and their respective employees, which include life insurance, accident & health insurance, group medical, dental, credit insurance, endowment and retirement & savings products written in Latin America. The Latin America segment also includes U.S. direct business, comprised of group and individual products sold through sponsoring organizations, affinity groups and direct to consumer. Products included are life, dental, group short- and long-term disability, AD&D coverages, property & casualty and other accident & health coverages, as well as non-insurance products such as identity protection.

Asia

The Asia segment offers a broad range of products to both individuals and corporations, as well as other institutions and their respective employees, which include whole life, term life, variable life, universal life, accident & health insurance, fixed and variable annuities, credit insurance and endowment products.

EMEA

The EMEA segment offers a broad range of products to both individuals and corporations, as well as other institutions and their respective employees, which include life insurance, accident & health insurance, credit insurance, annuities, endowment and retirement & savings products.



Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

2. Segment Information (continued)

Corporate & Other

Corporate & Other contains the excess capital, as well as certain charges and activities, not allocated to the segments, including external integration costs, internal resource costs for associates committed to acquisitions, enterprise-wide strategic initiative restructuring charges, various start-up businesses (including expatriate benefits insurance and the investment management business through which the Company offers fee-based investment management services to institutional clients) and certain run-off businesses. Corporate & Other also includes assumed reinsurance of certain variable annuity products from the Company's former operating joint venture in Japan. Under this in-force reinsurance agreement, the Company reinsures living and death benefit guarantees issued in connection with variable annuity products. Additionally, Corporate & Other includes interest expense related to the majority of the Company's outstanding debt and expenses associated with certain legal proceedings and income tax audit issues. Corporate & Other also includes the elimination of intersegment amounts, which generally relate to intersegment loans, which bear interest rates commensurate with related borrowings.

Financial Measures and Segment Accounting Policies

Operating earnings is the measure of segment profit or loss the Company uses to evaluate segment performance and allocate resources. Consistent with GAAP guidance for segment reporting, operating earnings is the Company's measure of segment performance and is reported below. Operating earnings should not be viewed as a substitute for income (loss) from continuing operations, net of income tax. The Company believes the presentation of operating earnings as the Company measures it for management purposes enhances the understanding of its performance by highlighting the results of operations and the underlying profitability drivers of the business.

Operating earnings is defined as operating revenues less operating expenses, both net of income tax.

Operating revenues and operating expenses exclude results of discontinued operations and other businesses that have been or will be sold or exited by MetLife and are referred to as divested businesses. Operating revenues also excludes net investment gains (losses) and net derivative gains (losses). Operating expenses also excludes goodwill impairments.

The following additional adjustments are made to GAAP revenues, in the line items indicated, in calculating operating revenues:

Universal life and investment-type product policy fees excludes the amortization of unearned revenue related to net investment gains (losses) and net derivative gains (losses) and certain variable annuity guaranteed minimum income benefits ("GMIBs") fees ("GMIB Fees");

Net investment income: (i) includes amounts for scheduled periodic settlement payments and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment, (ii) includes income from discontinued real estate operations, (iii) excludes post-tax operating earnings adjustments relating to insurance joint ventures accounted for under the equity method, (iv) excludes certain amounts related to contractholder-directed unit-linked investments, and (v) excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP; and

Other revenues are adjusted for settlements of foreign currency earnings hedges.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 2. Segment Information (continued)

The following additional adjustments are made to GAAP expenses, in the line items indicated, in calculating operating expenses:

Policyholder benefits and claims and policyholder dividends excludes: (i) changes in the policyholder dividend obligation related to net investment gains (losses) and net derivative gains (losses), (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments and amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass through adjustments, (iii) benefits and hedging costs related to GMIBs (“GMIB Costs”), and (iv) market value adjustments associated with surrenders or terminations of contracts (“Market Value Adjustments”);

Interest credited to policyholder account balances includes adjustments for scheduled periodic settlement payments and amortization of premium on derivatives that are hedges of policyholder account balances but do not qualify for hedge accounting treatment and excludes amounts related to net investment income earned on contractholder-directed unit-linked investments;

Amortization of deferred policy acquisition costs (“DAC”) and value of business acquired (“VOBA”) excludes amounts related to: (i) net investment gains (losses) and net derivative gains (losses), (ii) GMIB Fees and GMIB Costs, and (iii) Market Value Adjustments;

Amortization of negative VOBA excludes amounts related to Market Value Adjustments;

Interest expense on debt excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP; and

Other expenses excludes costs related to: (i) noncontrolling interests, (ii) implementation of new insurance regulatory requirements, and (iii) acquisition and integration costs.

Operating earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance. In addition to the tax impact of the adjustments mentioned above, provision for income tax expense (benefit) also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.

In the first quarter of 2015, the Company implemented certain segment reporting changes related to the (i) measurement of segment operating earnings, which included revising the Company’s capital allocation methodology, and (ii) the realignment of consumer direct business. Consequently, prior period results for the three months and nine months ended September 30, 2014 were impacted as follows:

Retail’s operating earnings increased (decreased) by \$86 million and \$135 million, net of (\$111) million and (\$200) million of income tax expense (benefit), respectively;

Group, Voluntary & Worksite Benefits’ operating earnings increased (decreased) by \$4 million and \$10 million, net of (\$2) million and \$2 million of income tax expense (benefit), respectively;

Corporate Benefit Funding’s operating earnings increased (decreased) by (\$13) million and (\$39) million, net of (\$10) million and (\$32) million of income tax expense (benefit), respectively;

Latin America’s operating earnings increased (decreased) by (\$30) million and (\$79) million, net of (\$16) million and (\$46) million of income tax expense (benefit), respectively;

Asia’s operating earnings increased (decreased) by \$4 million and \$14 million, net of \$3 million and \$5 million of income tax expense (benefit), respectively;

EMEA’s operating earnings increased (decreased) by (\$18) million and (\$56) million, net of (\$13) million and (\$31) million of income tax expense (benefit), respectively; and

Corporate & Other’s operating earnings increased (decreased) by (\$33) million and \$15 million, net of \$149 million and \$302 million of income tax expense (benefit), respectively.

Set forth in the tables below is certain financial information with respect to the Company’s segments, as well as Corporate & Other, for the three months and nine months ended September 30, 2015 and 2014. The segment accounting policies are the same as those used to prepare the Company’s consolidated financial statements, except for operating earnings adjustments as defined above. In addition, segment accounting policies include the method of

capital allocation described below.

11

---

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

2. Segment Information (continued)

Economic capital is an internally developed risk capital model, the purpose of which is to measure the risk in the business and to provide a basis upon which capital is deployed. The economic capital model accounts for the unique and specific nature of the risks inherent in the Company's business.

The Company's economic capital model, coupled with considerations of local capital requirements, aligns segment allocated equity with emerging standards and consistent risk principles. The model applies statistics-based risk evaluation principles to the material risks to which the Company is exposed. These consistent risk principles include calibrating required economic capital shock factors to a specific confidence level and time horizon while applying an industry standard method for the inclusion of diversification benefits among risk types. The Company's management is responsible for the ongoing production and enhancement of the economic capital model and reviews its approach periodically to ensure that it remains consistent with emerging industry practice standards.

Segment net investment income is credited or charged based on the level of allocated equity; however, changes in allocated equity do not impact the Company's consolidated net investment income, operating earnings or income (loss) from continuing operations, net of income tax.

Net investment income is based upon the actual results of each segment's specifically identifiable investment portfolios adjusted for allocated equity. Other costs are allocated to each of the segments based upon: (i) a review of the nature of such costs; (ii) time studies analyzing the amount of employee compensation costs incurred by each segment; and (iii) cost estimates included in the Company's product pricing.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 2. Segment Information (continued)

Three Months Ended September 30, 2015	Operating Results Americas									Adjustments	Total Consolidated	
	Retail	Group, Voluntary & Workplace Benefits	Corporate Benefit Funding	Latin America	Total	Asia	EMEA & Other	Corporate Total				
	(In millions)											
Revenues												
Premiums	\$1,806	\$4,092	\$1,555	\$668	\$8,121	\$1,736	\$501	\$18	\$10,376	\$(1)	\$10,375	
Universal life and investment-type product policy fees	1,229	188	55	261	1,733	382	106	26	2,247	99	2,346	
Net investment income	1,930	485	1,391	279	4,085	670	82	12	4,849	(890)	3,959	
Other revenues	241	113	70	11	435	26	11	23	495	(11)	484	
Net investment gains (losses)	—	—	—	—	—	—	—	—	—	382	382	
Net derivative gains (losses)	—	—	—	—	—	—	—	—	—	485	485	
Total revenues	5,206	4,878	3,071	1,219	14,374	2,814	700	79	17,967	64	18,031	
Expenses												
Policyholder benefits and claims and policyholder dividends	2,607	3,805	2,154	630	9,196	1,331	233	20	10,780	(92)	10,688	
Interest credited to policyholder account balances	550	39	295	88	972	327	27	5	1,331	(684)	647	
Capitalization of DAC	(266)	(41)	(1)	(105)	(413)	(435)	(107)	—	(955)	—	(955)	
Amortization of DAC and VOBA	432	40	6	57	535	309	127	—	971	160	1,131	
Amortization of negative VOBA	—	—	—	—	—	(77)	(5)	—	(82)	(8)	(90)	
Interest expense on debt	(1)	—	1	—	—	—	—	294	294	8	302	
Other expenses	1,197	666	113	410	2,386	896	352	492	4,126	19	4,145	
Total expenses	4,519	4,509	2,568	1,080	12,676	2,351	627	811	16,465	(597)	15,868	
Provision for income tax expense (benefit)	164	131	177	(37)	435	125	7	224	791	174	965	
Operating earnings	\$523	\$238	\$326	\$176	\$1,263	\$338	\$66	\$(956)	711			
Adjustments to:												
Total revenues									64			
Total expenses									597			
Provision for income tax (expense) benefit									(174)			
Income (loss) from continuing operations, net of income tax									\$1,198		\$1,198	

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 2. Segment Information (continued)

Three Months Ended September 30, 2014	Operating Results Americas								Adjustments	Total Consolidated	
	Retail	Group, Voluntary & Workplace Benefits	Corporate Benefit Funding	Latin America	Total	Asia	EMEA & Other	Corporate Total			
	(In millions)										
Revenues											
Premiums	\$1,869	\$4,010	\$451	\$812	\$7,142	\$1,939	\$581	\$23	\$9,685	\$18	\$9,703
Universal life and investment-type product policy fees	1,311	180	60	328	1,879	487	127	29	2,522	106	2,628
Net investment income	1,965	475	1,464	317	4,221	738	109	125	5,193	217	5,410
Other revenues	275	103	71	7	456	27	22	13	518	—	518
Net investment gains (losses)	—	—	—	—	—	—	—	—	—	109	109
Net derivative gains (losses)	—	—	—	—	—	—	—	—	—	478	478
Total revenues	5,420	4,768	2,046	1,464	13,698	3,191	839	190	17,918	928	18,846
Expenses											
Policyholder benefits and claims and policyholder dividends	2,555	3,729	1,033	735	8,052	1,535	252	15	9,854	5	9,859
Interest credited to policyholder account balances	567	38	279	97	981	394	43	8	1,426	391	1,817
Capitalization of DAC	(239 )	(37 )	(11 )	(112 )	(399 )	(507 )	(165 )	—	(1,071 )	—	(1,071 )
Amortization of DAC and VOBA	335	38	5	102	480	367	152	—	999	55	1,054
Amortization of negative VOBA	—	—	—	—	—	(89 )	(7 )	—	(96 )	(11 )	(107 )
Interest expense on debt	(1 )	—	2	—	1	—	—	291	292	3	295
Other expenses	1,163	634	133	450	2,380	1,027	463	133	4,003	44	4,047
Total expenses	4,380	4,402	1,441	1,272	11,495	2,727	738	447	15,407	487	15,894
Provision for income tax expense (benefit)	255	125	210	70	660	154	23	(181 )	656	202	858
Operating earnings	\$785	\$241	\$395	\$122	\$1,543	\$310	\$78	\$(76)	1,855		
Adjustments to:											
Total revenues									928		
Total expenses									(487 )		
Provision for income tax (expense) benefit									(202 )		
Income (loss) from continuing operations, net of income tax									\$2,094		\$2,094



Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 2. Segment Information (continued)

Nine Months Ended September 30, 2015	Operating Results Americas								Total	Adj.
	Retail	Group, Voluntary & Workplace Benefits	Corporate Benefit Funding	Latin America	Total	Asia	EMEA	Corporate & Other		
	(In millions)									
Revenues										
Premiums	\$5,302	\$12,313	\$2,292	\$2,150	\$22,057	\$5,297	\$1,534	\$54	\$28,942	\$(2)
Universal life and investment-type product policy fees	3,717	559	168	856	5,300	1,179	322	75	6,876	298
Net investment income	5,913	1,444	4,347	780	12,484	2,033	249	250	15,016	(649)
Other revenues	755	340	218	28	1,341	82	40	62	1,525	(28)
Net investment gains (losses)	—	—	—	—	—	—	—	—	—	535
Net derivative gains (losses)	—	—	—	—	—	—	—	—	—	394
Total revenues	15,687	14,656	7,025	3,814	41,182	8,591	2,145	441	52,359	548
Expenses										
Policyholder benefits and claims and policyholder dividends	7,429	11,445	4,078	1,955	24,907	4,046	737	40	29,730	237
Interest credited to policyholder account balances	1,643	114	882	263	2,902	992	91	19	4,004	(64)
Capitalization of DAC	(770)	(113)	(11)	(316)	(1,210)	(1,268)	(372)	—	(2,850)	—
Amortization of DAC and VOBA	1,207	120	17	221	1,565	971	388	1	2,925	128
Amortization of negative VOBA	—	—	—	(1)	(1)	(241)	(13)	—	(255)	(27)
Interest expense on debt	(2)	—	3	—	1	—	—	897	898	10
Other expenses	3,593	2,011	367	1,254	7,225	2,669	1,103	811	11,808	28
Total expenses	13,100	13,577	5,336	3,376	35,389	7,169	1,934	1,768	46,260	312
Provision for income tax expense (benefit)	721	382	588	15	1,706	332	25	(139)	1,924	(69)
Operating earnings	\$1,866	\$697	\$1,101	\$423	\$4,087	\$1,090	\$186	\$(1,188)	4,175	
Adjustments to:										
Total revenues									548	
Total expenses									(312)	
Provision for income tax (expense) benefit									69	
Income (loss) from continuing operations, net of income tax									\$4,480	

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 2. Segment Information (continued)

Nine Months Ended September 30, 2014	Operating Results Americas									Adjusted
	Retail	Group, Voluntary & Workplace Benefits	Corporate Benefit Funding	Latin America	Total	Asia	EMEA	Corporate & Other	Total	
	(In millions)									
Revenues										
Premiums	\$5,405	\$12,050	\$1,438	\$2,293	\$21,186	\$5,742	\$1,762	\$65	\$28,755	\$40
Universal life and investment-type product policy fees	3,814	538	172	956	5,480	1,276	353	96	7,205	302
Net investment income	5,906	1,396	4,259	915	12,476	2,162	328	407	15,373	331
Other revenues	785	314	214	23	1,336	78	49	39	1,502	(16)
Net investment gains (losses)	—	—	—	—	—	—	—	—	—	(427)
Net derivative gains (losses)	—	—	—	—	—	—	—	—	—	1,132
Total revenues	15,910	14,298	6,083	4,187	40,478	9,258	2,492	607	52,835	1,362
Expenses										
Policyholder benefits and claims and policyholder dividends	7,400	11,299	3,194	2,100	23,993	4,357	784	57	29,191	680
Interest credited to policyholder account balances	1,683	117	844	295	2,939	1,175	112	26	4,252	743
Capitalization of DAC	(722)	(107)	(30)	(320)	(1,179)	(1,458)	(511)	—	(3,148)	(1)
Amortization of DAC and VOBA	1,142	109	15	265	1,531	1,067	476	—	3,074	100
Amortization of negative VOBA	—	—	—	(1)	(1)	(275)	(22)	—	(298)	(35)
Interest expense on debt	(1)	—	6	—	5	—	—	880	885	34
Other expenses	3,486	1,900	377	1,322	7,085	2,995	1,383	470	11,933	59
Total expenses	12,988	13,318	4,406	3,661	34,373	7,861	2,222	1,433	45,889	1,580
Provision for income tax expense (benefit)	824	340	579	110	1,853	430	49	(454)	1,878	38
Operating earnings	\$2,098	\$640	\$1,098	\$416	\$4,252	\$967	\$221	\$(372)	5,068	
Adjustments to:										
Total revenues									1,362	
Total expenses									(1,580)	
Provision for income tax (expense) benefit									(38)	
Income (loss) from continuing operations, net of income tax									\$4,812	

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 2. Segment Information (continued)

The following table presents total assets with respect to the Company's segments, as well as Corporate & Other, at:

	September 30, 2015	December 31, 2014
	(In millions)	
Retail	\$347,126	\$359,188
Group, Voluntary & Worksite Benefits	47,443	46,483
Corporate Benefit Funding	227,297	228,543
Latin America	64,949	72,259
Asia	112,456	117,894
EMEA	27,698	29,217
Corporate & Other	55,491	48,753
Total	\$882,460	\$902,337

## 3. Insurance

## Guarantees

As discussed in Notes 1 and 4 of the Notes to the Consolidated Financial Statements included in the 2014 Annual Report, the Company issues variable annuity products with guaranteed minimum benefits. The portions of both non-life-contingent guaranteed minimum withdrawal benefits ("GMWBs") and the GMIBs that do not require annuitization are accounted for as embedded derivatives in policyholder account balances and are further discussed in Note 6.

The Company also issues two tier annuity contracts that apply a lower rate on funds deposited if the contractholder elects to surrender the contract for cash (the "lower tier") and a higher rate if the contractholder elects to annuitize (the "upper tier"). These guarantees include benefits that are payable in the event of death, maturity or at annuitization. Certain other annuity contracts contain guaranteed annuitization benefits that may be above what would be provided by the current account value of the contract. Additionally, the Company issues universal and variable life contracts where the Company contractually guarantees to the contractholder a secondary guarantee or a guaranteed paid-up benefit.

Based on the type of guarantee, the Company defines net amount at risk as listed below. These amounts include direct and assumed business, but exclude offsets from hedging or ceded reinsurance, if any.

## Variable Annuities

## In the Event of Death

Defined as the death benefit less the total contract account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date and includes any additional contractual claims associated with riders purchased to assist with covering income taxes payable upon death.

## At Annuitization

Defined as the amount (if any) that would be required to be added to the total contract account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. This amount represents the Company's potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date, even though the contracts contain terms that allow annuitization of the guaranteed amount only after the 10th anniversary of the contract, which not all contractholders have achieved.

## Two Tier and Other Annuities

Two tier annuities are defined as the excess of the upper tier, adjusted for a profit margin, less the lower tier, as of the balance sheet date. Other annuities are defined as the amount (if any) that would be required to be added to the total contract account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. This amount represents the Company's potential economic exposure to

such guarantees in the event all contractholders were to annuitize on the balance sheet date.

17

---

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 3. Insurance (continued)

## Universal and Variable Life Contracts

Defined as the guarantee amount less the account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date.

Information regarding the types of guarantees relating to annuity contracts and universal and variable life contracts was as follows at:

	September 30, 2015		December 31, 2014	
	In the Event of Death (In millions)	At Annuitization	In the Event of Death (In millions)	At Annuitization
Annuity Contracts (1)				
Variable Annuities				
Total contract account value (2)	\$ 179,887	\$ 90,852	\$ 196,595	\$ 99,000
Separate account value	\$ 149,829	\$ 87,417	\$ 163,566	\$ 95,963
Net amount at risk (2)	\$ 11,374	\$ 2,909	\$ 4,230	\$ 1,770
Average attained age of contractholders	66 years	66 years	65 years	65 years
Two Tier and Other Annuities				
Account value	N/A	\$ 1,621	N/A	\$ 1,040
Net amount at risk	N/A	\$ 444	N/A	\$ 340
Average attained age of contractholders	N/A	53 years	N/A	50 years
	September 30, 2015		December 31, 2014	
	Secondary	Paid-Up	Secondary	Paid-Up
	Guarantees	Guarantees	Guarantees	Guarantees
	(In millions)			
Universal and Variable Life Contracts (1)				
Account value (general and separate account)	\$ 16,994	\$ 3,490	\$ 16,875	\$ 3,587
Net amount at risk	\$ 177,022	\$ 19,360	\$ 180,069	\$ 20,344
Average attained age of policyholders	57 years	62 years	56 years	61 years

(1) The Company's annuity and life contracts with guarantees may offer more than one type of guarantee in each contract. Therefore, the amounts listed above may not be mutually exclusive.

(2) Includes amounts, which are not reported on the consolidated balance sheets, from assumed business of certain variable annuity products from the Company's former operating joint venture in Japan.

## 4. Closed Block

On April 7, 2000 (the "Demutualization Date"), Metropolitan Life Insurance Company ("MLIC") converted from a mutual life insurance company to a stock life insurance company and became a wholly-owned subsidiary of MetLife, Inc. The conversion was pursuant to an order by the New York Superintendent of Insurance approving MLIC's plan of reorganization, as amended (the "Plan of Reorganization"). On the Demutualization Date, MLIC established a closed block for the benefit of holders of certain individual life insurance policies of MLIC.

Experience within the closed block, in particular mortality and investment yields, as well as realized and unrealized gains and losses, directly impact the policyholder dividend obligation. Amortization of the closed block DAC, which resides outside of the closed block, is based upon cumulative actual and expected earnings within the closed block. Accordingly, the Company's net income continues to be sensitive to the actual performance of the closed block. Closed block assets, liabilities, revenues and expenses are combined on a line-by-line basis with the assets, liabilities, revenues and expenses outside the closed block based on the nature of the particular item.



Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 4. Closed Block (continued)

Information regarding the closed block liabilities and assets designated to the closed block was as follows at:

	September 30, 2015	December 31, 2014
	(In millions)	
Closed Block Liabilities		
Future policy benefits	\$41,280	\$41,667
Other policy-related balances	275	265
Policyholder dividends payable	498	461
Policyholder dividend obligation	2,309	3,155
Current income tax payable	29	1
Other liabilities	474	646
Total closed block liabilities	44,865	46,195
Assets Designated to the Closed Block		
Investments:		
Fixed maturity securities available-for-sale, at estimated fair value	27,739	29,199
Equity securities available-for-sale, at estimated fair value	94	91
Mortgage loans	6,122	6,076
Policy loans	4,641	4,646
Real estate and real estate joint ventures	601	666
Other invested assets	1,203	1,065
Total investments	40,400	41,743
Cash and cash equivalents	266	227
Accrued investment income	484	477
Premiums, reinsurance and other receivables	106	67
Deferred income tax assets	286	289
Total assets designated to the closed block	41,542	42,803
Excess of closed block liabilities over assets designated to the closed block	3,323	3,392
Amounts included in accumulated other comprehensive income (loss) ("AOCI")		
Unrealized investment gains (losses), net of income tax	1,712	2,291
Unrealized gains (losses) on derivatives, net of income tax	63	28
Allocated to policyholder dividend obligation, net of income tax	(1,501)	(2,051)
Total amounts included in AOCI	274	268
Maximum future earnings to be recognized from closed block assets and liabilities	\$3,597	\$3,660

Information regarding the closed block policyholder dividend obligation was as follows:

	Nine Months Ended September 30, 2015	Year Ended December 31, 2014
	(In millions)	
Balance, beginning of period	\$3,155	\$1,771
Change in unrealized investment and derivative gains (losses)	(846)	1,384
Balance, end of period	\$2,309	\$3,155





Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 4. Closed Block (continued)

Information regarding the closed block revenues and expenses was as follows:

	Three Months		Nine Months	
	Ended		Ended	
	September 30,		September 30,	
	2015	2014	2015	2014
	(In millions)			
Revenues				
Premiums	\$447	\$461	\$1,334	\$1,380
Net investment income	487	516	1,500	1,568
Net investment gains (losses)	(9	) —	(8	) 8
Net derivative gains (losses)	13	17	25	13
Total revenues	938	994	2,851	2,969
Expenses				
Policyholder benefits and claims	635	620	1,886	1,889
Policyholder dividends	273	255	757	731
Other expenses	36	39	109	118
Total expenses	944	914	2,752	2,738
Revenues, net of expenses before provision for income tax expense (benefit)	(6	) 80	99	231
Provision for income tax expense (benefit)	(1	) 28	36	81
Revenues, net of expenses and provision for income tax expense (benefit)	\$(5	) \$52	\$63	\$150

MLIC charges the closed block with federal income taxes, state and local premium taxes and other state or local taxes, as well as investment management expenses relating to the closed block as provided in the Plan of Reorganization. MLIC also charges the closed block for expenses of maintaining the policies included in the closed block.

## 5. Investments

Fixed Maturity and Equity Securities Available-for-Sale

Fixed Maturity and Equity Securities Available-for-Sale by Sector

The following table presents the fixed maturity and equity securities available-for-sale (“AFS”) by sector. Redeemable preferred stock is reported within U.S. corporate and foreign corporate fixed maturity securities and non-redeemable preferred stock is reported within equity securities. Included within fixed maturity securities are structured securities including residential mortgage-backed securities (“RMBS”), commercial mortgage-backed securities (“CMBS”) and asset-backed securities (“ABS”).

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

	September 30, 2015					December 31, 2014				
	Cost or Amortized Cost (In millions)	Gross Gains	Unrealized Temporary Losses	OTTI Losses	Estimated Fair Value	Cost or Amortized Cost	Gross Gains	Unrealized Temporary Losses	OTTI Losses	Estimated Fair Value
Fixed maturity securities										
U.S. corporate	\$95,156	\$7,525	\$1,717	\$7	\$100,957	\$96,235	\$10,343	\$624	\$—	\$105,954
Foreign corporate	56,545	3,465	1,606	—	58,404	57,695	4,651	664	7	61,675
U.S. Treasury and agency	53,624	6,216	169	—	59,671	54,654	6,892	30	—	61,516
Foreign government	45,346	5,361	184	—	50,523	47,327	5,500	161	—	52,666
RMBS	38,696	1,720	288	78	40,050	38,064	2,102	214	106	39,846
State and political subdivision	13,678	1,863	53	9	15,479	12,922	2,291	26	—	15,187
CMBS (1)	12,001	437	77	(1)	12,362	13,762	615	46	(1)	14,332
ABS	14,157	162	181	6	14,132	14,121	240	112	—	14,249
Total fixed maturity securities	\$329,203	\$26,749	\$4,275	\$99	\$351,578	\$334,780	\$32,634	\$1,877	\$112	\$365,425
Equity securities										
Common stock	\$2,040	\$375	\$99	\$—	\$2,316	\$1,990	\$554	\$28	\$—	\$2,516
Non-redeemable preferred stock	1,056	75	48	—	1,083	1,086	68	39	—	1,115
Total equity securities	\$3,096	\$450	\$147	\$—	\$3,399	\$3,076	\$622	\$67	\$—	\$3,631

(1) The noncredit loss component of other-than-temporary-impairment (“OTTI”) losses for CMBS was in an unrealized gain position of \$1 million at both September 30, 2015 and December 31, 2014, due to increases in estimated fair value subsequent to initial recognition of noncredit losses on such securities. See also “— Net Unrealized Investment Gains (Losses).”

The Company held non-income producing fixed maturity securities with an estimated fair value of \$77 million and \$64 million with unrealized gains (losses) of \$28 million and \$28 million at September 30, 2015 and December 31, 2014, respectively.

## Maturities of Fixed Maturity Securities

The amortized cost and estimated fair value of fixed maturity securities, by contractual maturity date, were as follows at September 30, 2015:

	Due in One Year or Less	Due After One Year Through Five Years	Due After Five Years Through Ten Years	Due After Ten Years	Structured Securities	Total Fixed Maturity Securities
	(In millions)					
Amortized cost	\$13,401	\$72,334	\$70,970	\$107,644	\$64,854	\$329,203
Estimated fair value	\$13,476	\$75,724	\$74,741	\$121,093	\$66,544	\$351,578

Actual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities not due at a single maturity date have been presented in the year of final contractual maturity. Structured securities (RMBS, CMBS and ABS) are shown separately, as they are not due at a single maturity.

Continuous Gross Unrealized Losses for Fixed Maturity and Equity Securities AFS by Sector

The following table presents the estimated fair value and gross unrealized losses of fixed maturity and equity securities AFS in an unrealized loss position, aggregated by sector and by length of time that the securities have been in a continuous unrealized loss position.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

	September 30, 2015				December 31, 2014			
	Less than 12 Months		Equal to or Greater than 12 Months		Less than 12 Months		Equal to or Greater than 12 Months	
	Estimated Fair Value	Gross Unrealized Losses	Estimated Fair Value	Gross Unrealized Losses	Estimated Fair Value	Gross Unrealized Losses	Estimated Fair Value	Gross Unrealized Losses
(In millions, except number of securities)								
Fixed maturity securities								
U.S. corporate	\$23,232	\$1,323	\$3,027	\$401	\$11,389	\$331	\$4,658	\$293
Foreign corporate	14,386	1,043	3,343	563	9,410	505	2,074	166
U.S. Treasury and agency	3,180	167	303	2	8,927	12	1,314	18
Foreign government	2,881	118	433	66	1,085	80	630	81
RMBS	6,431	179	2,077	187	4,180	92	2,534	228
State and political subdivision	1,415	43	100	19	83	1	297	25
CMBS	2,401	46	600	30	1,268	23	934	22
ABS	5,772	116	2,240	71	4,456	57	1,440	55
Total fixed maturity securities	\$59,698	\$3,035	\$12,123	\$1,339	\$40,798	\$1,101	\$13,881	\$888
Equity securities								
Common stock	\$292	\$98	\$9	\$1	\$111	\$28	\$1	\$—
Non-redeemable preferred stock	89	3	183	45	67	2	192	37
Total equity securities	\$381	\$101	\$192	\$46	\$178	\$30	\$193	\$37
Total number of securities in an unrealized loss position	5,256		1,275		3,153		1,435	

## Evaluation of AFS Securities for OTTI and Evaluating Temporarily Impaired AFS Securities

As described more fully in Notes 1 and 8 of the Notes to the Consolidated Financial Statements included in the 2014 Annual Report, the Company performs a regular evaluation of all investment classes for impairment, including fixed maturity securities and equity securities, in accordance with its impairment policy, in order to evaluate whether such investments are other-than-temporarily impaired.

## Current Period Evaluation

Based on the Company's current evaluation of its AFS securities in an unrealized loss position in accordance with its impairment policy, and the Company's current intentions and assessments (as applicable to the type of security) about holding, selling and any requirements to sell these securities, the Company concluded that these securities were not other-than-temporarily impaired at September 30, 2015. Future OTTI will depend primarily on economic fundamentals, issuer performance (including changes in the present value of future cash flows expected to be collected), changes in credit ratings, collateral valuation, interest rates and credit spreads. If economic fundamentals deteriorate or if there are adverse changes in the above factors, OTTI may be incurred in upcoming periods. Gross unrealized losses on fixed maturity securities increased \$2.4 billion during the nine months ended September 30, 2015 to \$4.4 billion. The increase in gross unrealized losses for the nine months ended September 30, 2015 was primarily attributable to widening credit spreads, and to a lesser extent, the impact of weakening foreign currencies on non-functional currency denominated fixed maturity securities.

At September 30, 2015, \$295 million of the total \$4.4 billion of gross unrealized losses were from 62 fixed maturity securities with an unrealized loss position of 20% or more of amortized cost for six months or greater.

**Investment Grade Fixed Maturity Securities**

Of the \$295 million of gross unrealized losses on fixed maturity securities with an unrealized loss of 20% or more of amortized cost for six months or greater, \$217 million, or 74%, were related to gross unrealized losses on 34 investment grade fixed maturity securities. Unrealized losses on investment grade fixed maturity securities are principally related to widening credit spreads and, with respect to fixed-rate fixed maturity securities, rising interest rates since purchase.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

## Below Investment Grade Fixed Maturity Securities

Of the \$295 million of gross unrealized losses on fixed maturity securities with an unrealized loss of 20% or more of amortized cost for six months or greater, \$78 million, or 26%, were related to gross unrealized losses on 28 below investment grade fixed maturity securities. Unrealized losses on below investment grade fixed maturity securities are principally related to non-agency RMBS (primarily alternative residential mortgage loans) and foreign and U.S. corporate securities (primarily utility industry securities) and are the result of significantly wider credit spreads resulting from higher risk premiums since purchase, largely due to economic and market uncertainties including concerns over valuations of residential real estate supporting non-agency RMBS. Management evaluates non-agency RMBS based on actual and projected cash flows after considering the quality of underlying collateral, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying assets backing a particular security and the payment priority within the tranche structure of the security; and evaluates foreign and U.S. corporate securities based on factors such as expected cash flows and the financial condition and near-term and long-term prospects of the issuers.

## Equity Securities

Gross unrealized losses on equity securities increased \$80 million during the nine months ended September 30, 2015 to \$147 million. Of the \$147 million, \$31 million were from eight securities with gross unrealized losses of 20% or more of cost for 12 months or greater. Of the \$31 million, 58% were from securities rated A or better, and all were from financial services industry investment grade non-redeemable preferred stock securities.

## Mortgage Loans

## Mortgage Loans by Portfolio Segment

Mortgage loans are summarized as follows at:

	September 30, 2015		December 31, 2014		
	Carrying Value (In millions)	% of Total	Carrying Value (In millions)	% of Total	
Mortgage loans:					
Commercial	\$41,619	65.5	% \$41,088	68.3	%
Agricultural	12,771	20.1	12,378	20.6	
Residential	8,955	14.1	6,369	10.6	
Subtotal (1)	63,345	99.7	59,835	99.5	
Valuation allowances	(311)	(0.5)	(305)	(0.5)	)
Subtotal mortgage loans, net	63,034	99.2	59,530	99.0	
Residential — fair value option (“FVO”)	315	0.5	308	0.5	
Commercial mortgage loans held by CSEs — FVO	204	0.3	280	0.5	
Total mortgage loans, net	\$63,553	100.0	% \$60,118	100.0	%

Purchases of mortgage loans were \$1.0 billion and \$3.2 billion for the three months and nine months ended (1) September 30, 2015, respectively. Purchases of mortgage loans were \$2.1 billion and \$3.5 billion for the three months and nine months ended September 30, 2014, respectively.

See “— Variable Interest Entities” for discussion of consolidated securitization entities (“CSEs”).

Information on commercial, agricultural and residential mortgage loans is presented in the tables below. Information on residential — FVO and commercial mortgage loans held by CSEs — FVO is presented in Note 7. The Company elects the FVO for certain mortgage loans and related long-term debt that are managed on a total return basis.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

## Mortgage Loans, Valuation Allowance and Impaired Loans by Portfolio Segment

Mortgage loans by portfolio segment, by method of evaluation of credit loss, impaired mortgage loans including those modified in a troubled debt restructuring, and the related valuation allowances, were as follows at:

	Evaluated Individually for Credit Losses				Evaluated Collectively for Credit Losses			Impaired Loans
	Impaired Loans with a Valuation Allowance			Impaired Loans without a Valuation Allowance		Recorded Investment	Valuation Allowances	Carrying Value
	Unpaid Principal Balance	Recorded Investment	Valuation Allowances	Unpaid Principal Balance	Recorded Investment			
(In millions)								
September 30, 2015								
Commercial	\$7	\$ 7	\$ 7	\$76	\$ 76	\$41,536	\$ 208	\$76
Agricultural	50	47	3	12	12	12,712	38	56
Residential	—	—	—	118	109	8,846	55	109
Total	\$57	\$ 54	\$ 10	\$206	\$ 197	\$63,094	\$ 301	\$241
December 31, 2014								
Commercial	\$75	\$ 75	\$ 24	\$101	\$ 100	\$40,913	\$ 200	\$151
Agricultural	51	48	2	14	13	12,317	37	59
Residential	—	—	—	40	37	6,332	42	37
Total	\$126	\$ 123	\$ 26	\$155	\$ 150	\$59,562	\$ 279	\$247

The average recorded investment for impaired commercial, agricultural and residential mortgage loans was \$118 million, \$62 million and \$96 million, respectively, for the three months ended September 30, 2015; and \$144 million, \$62 million and \$72 million, respectively, for the nine months ended September 30, 2015.

The average recorded investment for impaired commercial, agricultural and residential mortgage loans was \$302 million, \$69 million and \$17 million, respectively, for the three months ended September 30, 2014; and \$405 million, \$84 million and \$15 million, respectively, for the nine months ended September 30, 2014.

## Valuation Allowance Rollforward by Portfolio Segment

The changes in the valuation allowance, by portfolio segment, were as follows:

	Nine Months Ended September 30, 2015				2014			
	Commercial	Agricultural	Residential	Total	Commercial	Agricultural	Residential	Total
	(In millions)							
Balance, beginning of period	\$224	\$ 39	\$ 42	\$305	\$258	\$ 44	\$ 20	\$322
Provision (release)	3	2	27	32	(8	) (5	) 25	12
Charge-offs, net of recoveries	(12	) —	(14	) (26	) (23	) (1	) (3	) (27
Balance, end of period	\$215	\$ 41	\$ 55	\$311	\$227	\$ 38	\$ 42	\$307

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

## Credit Quality of Commercial Mortgage Loans

The credit quality of commercial mortgage loans was as follows at:

	Recorded Investment			Total	% of Total	Estimated Fair Value	% of Total		
	Debt Service Coverage Ratios								
	> 1.20x	1.00x - 1.20x	< 1.00x						
	(In millions)					(In millions)			
September 30, 2015									
Loan-to-value ratios									
Less than 65%	\$34,881	\$ 1,034	\$527	\$36,442	87.6	% \$37,984	88.0	%	
65% to 75%	3,997	217	68	4,282	10.3	4,296	10.0		
76% to 80%	47	—	8	55	0.1	55	0.1		
Greater than 80%	356	258	226	840	2.0	838	1.9		
Total	\$39,281	\$ 1,509	\$829	\$41,619	100.0	% \$43,173	100.0	%	
December 31, 2014									
Loan-to-value ratios									
Less than 65%	\$33,933	\$ 1,105	\$1,101	\$36,139	88.0	% \$38,166	88.4	%	
65% to 75%	3,306	405	87	3,798	9.2	3,873	9.0		
76% to 80%	130	—	15	145	0.4	153	0.3		
Greater than 80%	562	281	163	1,006	2.4	987	2.3		
Total	\$37,931	\$ 1,791	\$1,366	\$41,088	100.0	% \$43,179	100.0	%	

## Credit Quality of Agricultural Mortgage Loans

The credit quality of agricultural mortgage loans was as follows at:

	September 30, 2015		December 31, 2014		
	Recorded Investment (In millions)	% of Total	Recorded Investment (In millions)	% of Total	
Loan-to-value ratios					
Less than 65%	\$12,093	94.7	% \$11,743	94.9	%
65% to 75%	588	4.6	533	4.3	
76% to 80%	22	0.2	17	0.1	
Greater than 80%	68	0.5	85	0.7	
Total	\$12,771	100.0	% \$12,378	100.0	%

The estimated fair value of agricultural mortgage loans was \$13.2 billion and \$12.8 billion at September 30, 2015 and December 31, 2014, respectively.

## Credit Quality of Residential Mortgage Loans

The credit quality of residential mortgage loans was as follows at:

	September 30, 2015		December 31, 2014		
	Recorded Investment (In millions)	% of Total	Recorded Investment (In millions)	% of Total	
Performance indicators					
Performing	\$8,696	97.1	% \$6,196	97.3	%
Nonperforming	259	2.9	173	2.7	
Total	\$8,955	100.0	% \$6,369	100.0	%





Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

The estimated fair value of residential mortgage loans was \$9.2 billion and \$6.6 billion at September 30, 2015 and December 31, 2014, respectively.

## Past Due and Interest Accrual Status of Mortgage Loans

The Company has a high quality, well performing mortgage loan portfolio, with 99% of all mortgage loans classified as performing at both September 30, 2015 and December 31, 2014. The Company defines delinquency consistent with industry practice, when mortgage loans are past due as follows: commercial and residential mortgage loans — 60 days and agricultural mortgage loans — 90 days. The past due and accrual status of mortgage loans at recorded investment, prior to valuation allowances, by portfolio segment, were as follows at:

	Past Due		Nonaccrual Status	
	September 30, 2015	December 31, 2014	September 30, 2015	December 31, 2014
	(In millions)			
Commercial	\$9	\$10	\$7	\$75
Agricultural	109	1	46	41
Residential	259	173	248	163
Total	\$377	\$184	\$301	\$279

## Mortgage Loans Modified in a Troubled Debt Restructuring

For a small portion of the mortgage loan portfolio, classified as troubled debt restructurings, concessions are granted related to borrowers experiencing financial difficulties. Generally, the types of concessions include: reduction of the contractual interest rate, extension of the maturity date at an interest rate lower than current market interest rates, and/or a reduction of accrued interest. The amount, timing and extent of the concession granted is considered in determining any impairment or changes in the specific valuation allowance. During both the three months and nine months ended September 30, 2015 and 2014, the Company did not have a significant amount of mortgage loans modified in a troubled debt restructuring.

## Cash Equivalents

The carrying value of cash equivalents, which includes securities and other investments with an original or remaining maturity of three months or less at the time of purchase, was \$5.0 billion and \$4.5 billion at September 30, 2015 and December 31, 2014, respectively.

## Net Unrealized Investment Gains (Losses)

Unrealized investment gains (losses) on fixed maturity and equity securities AFS and the effect on DAC, VOBA, deferred sales inducements (“DSI”), future policy benefits and the policyholder dividend obligation, that would result from the realization of the unrealized gains (losses), are included in net unrealized investment gains (losses) in AOCI. The components of net unrealized investment gains (losses), included in AOCI, were as follows:

	September 30, 2015	December 31, 2014
	(In millions)	
Fixed maturity securities	\$22,105	\$30,367
Fixed maturity securities with noncredit OTTI losses in AOCI	(99)	(112)
Total fixed maturity securities	22,006	30,255
Equity securities	372	608
Derivatives	2,145	1,761
Other	287	149
Subtotal	24,810	32,773
Amounts allocated from:		
Future policy benefits	(183)	(2,886)
DAC and VOBA related to noncredit OTTI losses recognized in AOCI	—	(4)
DAC, VOBA and DSI	(1,456)	(1,946)

Edgar Filing: METLIFE INC - Form 10-Q

Policyholder dividend obligation	(2,309	) (3,155	)
Subtotal	(3,948	) (7,991	)
Deferred income tax benefit (expense) related to noncredit OTTI losses recognized in AOCI	26	42	
Deferred income tax benefit (expense)	(7,210	) (8,556	)
Net unrealized investment gains (losses)	13,678	16,268	
Net unrealized investment gains (losses) attributable to noncontrolling interests	(44	) (33	)
Net unrealized investment gains (losses) attributable to MetLife, Inc.	\$13,634	\$16,235	

The changes in fixed maturity securities with noncredit OTTI losses included in AOCI were as follows:

	Nine Months Ended September 30, 2015	Year Ended December 31, 2014	
	(In millions)		
Balance, beginning of period	\$(112	) \$(218	)
Noncredit OTTI losses and subsequent changes recognized	(4	) 17	
Securities sold with previous noncredit OTTI loss	107	53	
Subsequent changes in estimated fair value	(90	) 36	
Balance, end of period	\$(99	) \$(112	)

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

The changes in net unrealized investment gains (losses) were as follows:

	Nine Months Ended September 30, 2015 (In millions)	
Balance, beginning of period	\$16,235	
Fixed maturity securities on which noncredit OTTI losses have been recognized	13	
Unrealized investment gains (losses) during the period	(7,976	)
Unrealized investment gains (losses) relating to:		
Future policy benefits	2,703	
DAC and VOBA related to noncredit OTTI losses recognized in AOCI	4	
DAC, VOBA and DSI	490	
Policyholder dividend obligation	846	
Deferred income tax benefit (expense) related to noncredit OTTI losses recognized in AOCI	(16	)
Deferred income tax benefit (expense)	1,346	
Net unrealized investment gains (losses)	13,645	
Net unrealized investment gains (losses) attributable to noncontrolling interests	(11	)
Balance, end of period	\$13,634	
Change in net unrealized investment gains (losses)	\$(2,590	)
Change in net unrealized investment gains (losses) attributable to noncontrolling interests	(11	)
Change in net unrealized investment gains (losses) attributable to MetLife, Inc.	\$(2,601	)

## Concentrations of Credit Risk

Investments in any counterparty that were greater than 10% of the Company's equity, other than the U.S. government and its agencies, were in fixed income securities of the Japanese government and its agencies with an estimated fair value of \$20.9 billion and \$20.3 billion at September 30, 2015 and December 31, 2014, respectively. The Company's investment in fixed maturity and equity securities to counterparties that primarily conduct business in Japan, including Japan government and agency fixed maturity securities, was \$25.9 billion and \$25.5 billion at September 30, 2015 and December 31, 2014, respectively.

## Securities Lending

The Company participates in a securities lending program whereby securities are loaned to third parties, primarily brokerage firms and commercial banks. The Company obtains collateral, usually cash, in an amount generally equal to 102% of the estimated fair value of the securities loaned at inception of the loan. Securities loaned under such transactions may be sold or re-pledged by the transferee. The Company monitors the estimated fair value of the securities loaned on a daily basis with additional collateral obtained as necessary throughout the duration of the loan. Elements of the securities lending program are presented below at:

	September 30, 2015	December 31, 2014
	(In millions)	
Securities on loan: (1)		
Amortized cost	\$27,147	\$26,989
Estimated fair value	\$29,848	\$30,269
Cash collateral on deposit from counterparties (2)	\$30,384	\$30,826
Security collateral on deposit from counterparties (3)	\$175	\$83
Reinvestment portfolio — estimated fair value	\$30,560	\$31,314



Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

Included within fixed maturity securities and short-term investments. At September 30, 2015, both amortized cost (1) and estimated fair value also include \$227 million, at estimated fair value, of securities which are not reflected in the consolidated financial statements.

(2) Included within payables for collateral under securities loaned and other transactions.

(3) Security collateral on deposit from counterparties may not be sold or re-pledged, unless the counterparty is in default, and is not reflected in the consolidated financial statements.

The cash collateral liability by loaned security type and remaining tenor of the agreements were as follows at:

September 30, 2015

Remaining Tenor of Securities Lending Agreements

	Open (1)	1 Month or Less	1 to 6 Months	6 Months to 1 Year	Total	% of Total	
(In millions)							
Cash collateral liability by loaned security type							
U.S. Treasury and agency	\$10,199	\$11,215	\$5,398	\$435	\$27,247	89.7	%
Agency RMBS	—	986	658	—	1,644	5.4	
Foreign government	2	979	216	—	1,197	3.9	
U.S. corporate	10	285	—	—	295	1.0	
Foreign corporate	1	—	—	—	1	—	
Total	\$10,212	\$13,465	\$6,272	\$435	\$30,384	100.0	%

December 31, 2014

Remaining Tenor of Securities Lending Agreements

	Open (1)	1 Month or Less	1 to 6 Months	6 Months to 1 Year	Total	% of Total	
(In millions)							
Cash collateral liability by loaned security type							
U.S. Treasury and agency	\$10,371	\$10,423	\$5,239	\$—	\$26,033	84.5	%
Agency RMBS	—	482	2,572	—	3,054	9.9	
Foreign government	30	1,034	81	—	1,145	3.7	
U.S. corporate	125	182	—	—	307	1.0	
Foreign corporate	175	112	—	—	287	0.9	
Total	\$10,701	\$12,233	\$7,892	\$—	\$30,826	100.0	%

(1) The related loaned security could be returned to the Company on the next business day which would require the Company to immediately return the cash collateral.

If the Company is required to return significant amounts of cash collateral on short notice and is forced to sell securities to meet the return obligation, it may have difficulty selling such collateral that is invested in securities in a timely manner, be forced to sell securities in a volatile or illiquid market for less than what otherwise would have been realized under normal market conditions, or both. The estimated fair value of the securities on loan related to the cash collateral on open at September 30, 2015 was \$10.0 billion, over 99% of which were U.S. Treasury and agency securities which, if put back to the Company, could be immediately sold to satisfy the cash requirement.

The reinvestment portfolio acquired with the cash collateral consisted principally of fixed maturity securities (including U.S. Treasury and agency, agency RMBS, ABS, U.S. and foreign corporate securities and non-agency RMBS) with over 60% invested in U.S. Treasury and agency securities, agency RMBS, short-term investments, or held in cash and cash equivalents. If the securities on loan or the reinvestment portfolio become less liquid, the

Company has the liquidity resources of most of its general account available to meet any potential cash demands when securities on loan are put back to the Company.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

## Repurchase Agreement Transactions

Commencing in the first quarter of 2015, the Company began participating in short-term repurchase agreements and reverse repurchase agreements with unaffiliated financial institutions. Under these agreements, the Company lends fixed maturity securities and contemporaneously borrows other fixed maturity securities (e.g., repurchase and reverse repurchase, respectively). The Company obtains cash collateral in an amount greater than or equal to 95% of the estimated fair value of the securities loaned, and pledges cash collateral in an amount generally equal to 98% of the estimated fair value of the borrowed securities at the inception of the transaction. The Company monitors the estimated fair value of the securities loaned and borrowed on a daily basis with additional collateral obtained as necessary throughout the duration of the transaction.

The Company accounted for these transactions as collateralized borrowing and lending. The amount of fixed maturity securities lent and borrowed, at estimated fair value, was \$524 million and \$512 million, respectively, at September 30, 2015. Securities loaned under such transactions may be sold or re-pledged by the transferee. Securities borrowed under such transactions may be re-pledged and are not reflected in the consolidated financial statements. The amount of borrowed securities which were re-pledged was \$227 million, at estimated fair value, at September 30, 2015.

The Company has elected to offset amounts recognized as receivables and payables resulting from these transactions. The gross amounts of the receivables and payables related to these transactions at September 30, 2015 were both \$499 million. After the effect of offsetting of \$499 million, the net amount presented in the consolidated balance sheet at September 30, 2015 was a liability of less than \$1 million. Amounts owed to and due from counterparties may be settled in cash or offset, in accordance with the agreements. Cash inflows and outflows for cash settlements are reported on the consolidated statements of cash flows. At September 30, 2015, all \$499 million of payables from repurchase agreements had a remaining tenor of one to three months and were loans of U.S. and foreign corporate securities.

See Note 6 for information regarding the estimated fair value of the Company's net derivative assets and net derivative liabilities after the application of master netting agreements and collateral.

## Invested Assets on Deposit, Held in Trust and Pledged as Collateral

Invested assets on deposit, held in trust and pledged as collateral are presented below at estimated fair value for all asset classes, except mortgage loans, which are presented at carrying value at:

	September 30, 2015	December 31, 2014
	(In millions)	
Invested assets on deposit (regulatory deposits)	\$9,146	\$9,437
Invested assets held in trust (collateral financing arrangements and reinsurance agreements)	10,285	10,069
Invested assets pledged as collateral (1)	24,646	25,996
Total invested assets on deposit, held in trust and pledged as collateral	\$44,077	\$45,502

The Company has pledged invested assets in connection with various agreements and transactions, including funding agreements (see Notes 4 and 12 of the Notes to the Consolidated Financial Statements included in the (1) 2014 Annual Report), collateral financing arrangements (see Note 13 of the Notes to the Consolidated Financial Statements included in the 2014 Annual Report) and derivative transactions (see Note 6).

See “— Securities Lending” and “— Repurchase Agreement Transactions” for information regarding securities on loan and Note 4 for information regarding investments designated to the closed block.

## Variable Interest Entities

The Company has invested in certain structured transactions (including CSEs), formed trusts to invest proceeds from certain collateral financing arrangements and has insurance operations that are VIEs. In certain instances, the



Company holds both the power to direct the most significant activities of the entity, as well as an economic interest in the entity and, as such, is deemed to be the primary beneficiary or consolidator of the entity.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

The determination of the VIE's primary beneficiary requires an evaluation of the contractual and implied rights and obligations associated with each party's relationship with or involvement in the entity, an estimate of the entity's expected losses and expected residual returns and the allocation of such estimates to each party involved in the entity. The Company generally uses a qualitative approach to determine whether it is the primary beneficiary. However, for VIEs that are investment companies or apply measurement principles consistent with those utilized by investment companies, the primary beneficiary is based on a risks and rewards model and is defined as the entity that will absorb a majority of a VIE's expected losses, receive a majority of a VIE's expected residual returns if no single entity absorbs a majority of expected losses, or both. The Company reassesses its involvement with VIEs on a quarterly basis. The use of different methodologies, assumptions and inputs in the determination of the primary beneficiary could have a material effect on the amounts presented within the consolidated financial statements.

## Consolidated VIEs

The following table presents the total assets and total liabilities relating to VIEs for which the Company has concluded that it is the primary beneficiary and which are consolidated at September 30, 2015 and December 31, 2014. Creditors or beneficial interest holders of VIEs where the Company is the primary beneficiary have no recourse to the general credit of the Company, as the Company's obligation to the VIEs is limited to the amount of its committed investment.

	September 30, 2015		December 31, 2014	
	Total	Total	Total	Total
	Assets	Liabilities	Assets	Liabilities
	(In millions)			
MRSC (collateral financing arrangement (primarily securities)) (1)	\$3,399	\$—	\$3,471	\$—
Operating joint venture (2)	2,445	2,045	2,405	1,999
CSEs (assets (primarily loans) and liabilities (primarily debt)) (3)	219	74	297	155
Investments:				
Mortgage loans	86	86	—	—
Other invested assets	46	—	59	—
FVO and trading securities	—	—	45	—
Other limited partnership interests	29	—	37	—
Real estate joint ventures	—	—	9	15
Total	\$6,224	\$2,205	\$6,323	\$2,169

(1) See Note 13 of the Notes to the Consolidated Financial Statements included in the 2014 Annual Report for a description of the MetLife Reinsurance Company of South Carolina ("MRSC") collateral financing arrangement.

Assets of the operating joint venture are primarily fixed maturity securities and separate account assets. Liabilities (2) of the operating joint venture are primarily future policy benefits, other policyholder funds and separate account liabilities.

The Company consolidates entities that are structured as CMBS and as collateralized debt obligations. The assets of these entities can only be used to settle their respective liabilities, and under no circumstances is the Company liable for any principal or interest shortfalls should any arise. The Company's exposure was limited to that of its remaining investment in these entities of \$126 million and \$123 million at estimated fair value at September 30, (3) 2015 and December 31, 2014, respectively. The long-term debt bears interest primarily at fixed rates ranging from 2.25% to 5.57%, payable primarily on a monthly basis. Interest expense related to these obligations, included in other expenses, was \$8 million and \$10 million for the three months and nine months ended September 30, 2015, respectively, and \$3 million and \$34 million for the three months and nine months ended September 30, 2014, respectively.



Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

## Unconsolidated VIEs

The carrying amount and maximum exposure to loss relating to VIEs in which the Company holds a significant variable interest but is not the primary beneficiary and which have not been consolidated were as follows at:

	September 30, 2015		December 31, 2014	
	Carrying Amount	Maximum Exposure to Loss (1)	Carrying Amount	Maximum Exposure to Loss (1)
	(In millions)			
Fixed maturity securities AFS:				
Structured securities (RMBS, CMBS and ABS) (2)	\$66,544	\$66,544	\$68,427	\$68,427
U.S. and foreign corporate	3,324	3,324	3,829	3,829
Other limited partnership interests	6,004	8,162	6,250	8,402
Other invested assets	1,587	2,007	1,720	2,050
FVO and trading securities	577	577	565	565
Real estate joint ventures	72	90	100	125
Mortgage loans	34	34	51	51
Equity securities AFS:				
Non-redeemable preferred stock	39	39	41	41
Total	\$78,181	\$80,777	\$80,983	\$83,490

The maximum exposure to loss relating to fixed maturity securities AFS, FVO and trading securities and equity securities AFS is equal to their carrying amounts or the carrying amounts of retained interests. The maximum exposure to loss relating to other limited partnership interests, mortgage loans and real estate joint ventures is equal to the carrying amounts plus any unfunded commitments. For certain of its investments in other invested assets, the

(1) Company's return is in the form of income tax credits which are guaranteed by creditworthy third parties. For such investments, the maximum exposure to loss is equal to the carrying amounts plus any unfunded commitments, reduced by income tax credits guaranteed by third parties of \$188 million and \$212 million at September 30, 2015 and December 31, 2014, respectively. Such a maximum loss would be expected to occur only upon bankruptcy of the issuer or investee.

(2) For these variable interests, the Company's involvement is limited to that of a passive investor in mortgage-backed or asset-backed securities issued by trusts that do not have substantial equity.

As described in Note 14, the Company makes commitments to fund partnership investments in the normal course of business. Excluding these commitments, the Company did not provide financial or other support to investees designated as VIEs during both the nine months ended September 30, 2015 and 2014.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

## Net Investment Income

The components of net investment income were as follows:

	Three Months		Nine Months	
	Ended		Ended	
	September 30,		September 30,	
	2015	2014	2015	2014
	(In millions)			
Investment income:				
Fixed maturity securities	\$3,525	\$3,695	\$10,738	\$11,106
Equity securities	36	31	102	98
FVO and trading securities — Actively Traded and FVO general account securities (1)	(35	) 14	4	95
Mortgage loans	786	775	2,317	2,192
Policy loans	147	158	450	473
Real estate and real estate joint ventures	233	245	767	724
Other limited partnership interests	216	299	681	834
Cash, cash equivalents and short-term investments	29	42	101	130
Operating joint ventures	(1	) 2	15	5
Other	28	60	180	136
Subtotal	4,964	5,321	15,355	15,793
Less: Investment expenses	308	298	923	873
Subtotal, net	4,656	5,023	14,432	14,920
FVO and trading securities — FVO contractholder-directed unit-linked investments (1)	(701	) 379	(79	) 739
FVO CSEs — interest income:				
Commercial mortgage loans	4	8	13	44
Securities	—	—	1	1
Subtotal	(697	) 387	(65	) 784
Net investment income	\$3,959	\$5,410	\$14,367	\$15,704

(1) Changes in estimated fair value subsequent to purchase for securities still held as of the end of the respective periods included in net investment income were as follows:

	Three Months		Nine Months	
	Ended		Ended	
	September 30,		September 30,	
	2015	2014	2015	2014
	(In millions)			
Actively Traded and FVO general account securities	\$(39	) \$(18	) \$(45	) \$7
FVO contractholder-directed unit-linked investments	\$(833	) \$248	\$(600	) \$329

See “— Variable Interest Entities” for discussion of CSEs.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

5. Investments (continued)

FVO and trading securities are primarily comprised of securities for which the FVO has been elected (“FVO Securities”). FVO Securities include certain fixed maturity and equity securities held-for-investment by the general account to support asset and liability management strategies for certain insurance products and investments in certain separate accounts. FVO Securities are primarily comprised of contractholder-directed investments supporting unit-linked variable annuity type liabilities which do not qualify for presentation as separate account summary total assets and liabilities. The investment returns on these investments inure to the contractholders and are offset by a corresponding change in policyholder account balances through interest credited to policyholder account balances. FVO Securities also include securities held by CSEs. The Company has a trading securities portfolio, principally invested in fixed maturity securities, to support investment strategies that involve the active and frequent purchase and sale of actively traded securities and the execution of short sale agreements.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

Net Investment Gains (Losses)

Components of Net Investment Gains (Losses)

The components of net investment gains (losses) were as follows:

	Three Months Ended September 30, 2015		2014		Nine Months Ended September 30, 2015		2014	
	(In millions)							
Total gains (losses) on fixed maturity securities:								
Total OTTI losses recognized — by sector and industry:								
U.S. and foreign corporate securities — by industry:								
Consumer	\$(17	)	\$—		\$(20	)	\$(7	)
Transportation	—		—		—		(2	)
Industrial	(3	)	—		(5	)	—	
Total U.S. and foreign corporate securities	(20	)	—		(25	)	(9	)
RMBS	(1	)	(18	)	(16	)	(27	)
ABS	—		—		—		(7	)
CMBS	—		(13	)	—		(13	)
State and political subdivision	(6	)	—		(6	)	—	
OTTI losses on fixed maturity securities recognized in earnings	(27	)	(31	)	(47	)	(56	)
Fixed maturity securities — net gains (losses) on sales and disposals	15		184		383		349	
Total gains (losses) on fixed maturity securities	88		153		336		293	
Total gains (losses) on equity securities:								
Total OTTI losses recognized — by sector:								
Non-redeemable preferred stock	(1	)	—		(1	)	(23	)
Common stock	(6	)	(1	)	(15	)	(12	)
OTTI losses on equity securities recognized in earnings	(7	)	(1	)	(16	)	(35	)
Equity securities — net gains (losses) on sales and disposals	14		15		39		99	
Total gains (losses) on equity securities	7		14		23		64	
FVO and trading securities — FVO general account securities	—		—		—		8	
Mortgage loans	(26	)	(30	)	(78	)	(25	)
Real estate and real estate joint ventures	263		86		257		150	
Other limited partnership interests	(59	)	(14	)	(52	)	(52	)
Other investment portfolio gains (losses)	18		(20	)	14		(26	)
Subtotal — investment portfolio gains (losses)	291		189		500		412	
FVO CSEs:								
Commercial mortgage loans	(4	)	1		(6	)	(14	)
Long-term debt — related to commercial mortgage loans	1		3		3		21	
Long-term debt — related to securities	—		(1	)	—		(1	)
Non-investment portfolio gains (losses) (1)	94		(83	)	38		(845	)
Subtotal FVO CSEs and non-investment portfolio gains (losses)	91		(80	)	35		(839	)
Total net investment gains (losses)	\$382		\$109		\$535		\$(427	)

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

There were no non-investment portfolio gains (losses) for the three months ended September 30, 2014 related to the disposition of MetLife Assurance Limited (“MAL”). Non-investment portfolio gains (losses) for the nine months (1) ended September 30, 2014 includes a loss of \$633 million related to the disposition of MAL. See Note 3 of the Notes to the Consolidated Financial Statements included in the 2014 Annual Report.

See “— Variable Interest Entities” for discussion of CSEs.

Gains (losses) from foreign currency transactions included within net investment gains (losses) were \$53 million and (\$29) million for the three months and nine months ended September 30, 2015, respectively, and (\$118) million and (\$225) million for the three months and nine months ended September 30, 2014, respectively.

## Sales or Disposals and Impairments of Fixed Maturity and Equity Securities

Proceeds from sales or disposals of fixed maturity and equity securities and the components of fixed maturity and equity securities net investment gains (losses) were as shown in the tables below. Investment gains and losses on sales of securities are determined on a specific identification basis.

	Three Months Ended September 30,			
	2015	2014	2015	2014
	Fixed Maturity Securities		Equity Securities	
	(In millions)			
Proceeds	\$27,264	\$20,105	\$55	\$96
Gross investment gains	\$371	\$297	\$20	\$21
Gross investment losses	(256	) (113	) (6	) (6
OTTI losses	(27	) (31	) (7	) (1
Net investment gains (losses)	\$88	\$153	\$7	\$14
	Nine Months Ended September 30,			
	2015	2014	2015	2014
	Fixed Maturity Securities		Equity Securities	
	(In millions)			
Proceeds	\$86,590	\$62,096	\$211	\$523
Gross investment gains	\$1,047	\$787	\$54	\$108
Gross investment losses	(664	) (438	) (15	) (9
OTTI losses	(47	) (56	) (16	) (35
Net investment gains (losses)	\$336	\$293	\$23	\$64



Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 5. Investments (continued)

## Credit Loss Rollforward

The table below presents a rollforward of the cumulative credit loss component of OTTI loss recognized in earnings on fixed maturity securities still held for which a portion of the OTTI loss was recognized in other comprehensive income (loss) (“OCI”):

	Three Months Ended September 30, 2015		Nine Months Ended September 30, 2015	
	2014	2014	2014	2014
	(In millions)			
Balance, beginning of period	\$280	\$359	\$357	\$378
Additions:				
Initial impairments — credit loss OTTI on securities not previously impaired	—	1	2	1
Additional impairments — credit loss OTTI on securities previously impaired	—	15	14	23
Reductions:				
Sales (maturities, pay downs or prepayments) of securities previously impaired as credit loss OTTI	(22	) (11	) (113	) (31
Securities impaired to net present value of expected future cash flows	—	—	—	(7
Increase in cash flows — accretion of previous credit loss OTTI	(1	) —	(2	) —
Balance, end of period	\$258	\$364	\$258	\$364

## 6. Derivatives

## Accounting for Derivatives

## Freestanding Derivatives

Freestanding derivatives are carried on the Company’s balance sheet either as assets within other invested assets or as liabilities within other liabilities at estimated fair value. The Company does not offset the estimated fair value amounts recognized for derivatives executed with the same counterparty under the same master netting agreement.

Accruals on derivatives are generally recorded in accrued investment income or within other liabilities. However, accruals that are not scheduled to settle within one year are included with the derivatives carrying value in other invested assets or other liabilities.

If a derivative is not designated as an accounting hedge or its use in managing risk does not qualify for hedge accounting, changes in the estimated fair value of the derivative are reported in net derivative gains (losses) except as follows:

## Statement of Operations Presentation:

Policyholder benefits and claims

Net investment income

## Derivative:

- Economic hedges of variable annuity guarantees included in future policy benefits
- Economic hedges of equity method investments in joint ventures
- All derivatives held in relation to trading portfolios
- Derivatives held within contractholder-directed unit-linked investments

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 6. Derivatives (continued)

## Hedge Accounting

To qualify for hedge accounting, at the inception of the hedging relationship, the Company formally documents its risk management objective and strategy for undertaking the hedging transaction, as well as its designation of the hedge. Hedge designation and financial statement presentation of changes in estimated fair value of the hedging derivatives are as follows:

Fair value hedge (a hedge of the estimated fair value of a recognized asset or liability) - in net derivative gains (losses), consistent with the change in estimated fair value of the hedged item attributable to the designated risk being hedged.

Cash flow hedge (a hedge of a forecasted transaction or of the variability of cash flows to be received or paid related to a recognized asset or liability) - effectiveness in OCI (deferred gains or losses on the derivative are reclassified into the statement of operations when the Company's earnings are affected by the variability in cash flows of the hedged item); ineffectiveness in net derivative gains (losses).

Net investment in a foreign operation hedge - effectiveness in OCI, consistent with the translation adjustment for the hedged net investment in the foreign operation; ineffectiveness in net derivative gains (losses).

The changes in estimated fair values of the hedging derivatives are exclusive of any accruals that are separately reported on the statement of operations within interest income or interest expense to match the location of the hedged item. Accruals on derivatives in net investment hedges are recognized in OCI.

In its hedge documentation, the Company sets forth how the hedging instrument is expected to hedge the designated risks related to the hedged item and sets forth the method that will be used to retrospectively and prospectively assess the hedging instrument's effectiveness and the method that will be used to measure ineffectiveness. A derivative designated as a hedging instrument must be assessed as being highly effective in offsetting the designated risk of the hedged item. Hedge effectiveness is formally assessed at inception and at least quarterly throughout the life of the designated hedging relationship. Assessments of hedge effectiveness and measurements of ineffectiveness are also subject to interpretation and estimation and different interpretations or estimates may have a material effect on the amount reported in net income.

The Company discontinues hedge accounting prospectively when: (i) it is determined that the derivative is no longer highly effective in offsetting changes in the estimated fair value or cash flows of a hedged item; (ii) the derivative expires, is sold, terminated, or exercised; (iii) it is no longer probable that the hedged forecasted transaction will occur; or (iv) the derivative is de-designated as a hedging instrument.

When hedge accounting is discontinued because it is determined that the derivative is not highly effective in offsetting changes in the estimated fair value or cash flows of a hedged item, the derivative continues to be carried on the balance sheet at its estimated fair value, with changes in estimated fair value recognized in net derivative gains (losses). The carrying value of the hedged recognized asset or liability under a fair value hedge is no longer adjusted for changes in its estimated fair value due to the hedged risk, and the cumulative adjustment to its carrying value is amortized into income over the remaining life of the hedged item. Provided the hedged forecasted transaction is still probable of occurrence, the changes in estimated fair value of derivatives recorded in OCI related to discontinued cash flow hedges are released into the statement of operations when the Company's earnings are affected by the variability in cash flows of the hedged item.

When hedge accounting is discontinued because it is no longer probable that the forecasted transactions will occur on the anticipated date or within two months of that date, the derivative continues to be carried on the balance sheet at its estimated fair value, with changes in estimated fair value recognized currently in net derivative gains (losses).

Deferred gains and losses of a derivative recorded in OCI pursuant to the discontinued cash flow hedge of a forecasted transaction that is no longer probable are recognized immediately in net derivative gains (losses).

In all other situations in which hedge accounting is discontinued, the derivative is carried at its estimated fair value on the balance sheet, with changes in its estimated fair value recognized in the current period as net derivative gains (losses).



Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

6. Derivatives (continued)

Embedded Derivatives

The Company sells variable annuities and issues certain insurance products and investment contracts and is a party to certain reinsurance agreements that have embedded derivatives. The Company assesses each identified embedded derivative to determine whether it is required to be bifurcated. The embedded derivative is bifurcated from the host contract and accounted for as a freestanding derivative if:

• the combined instrument is not accounted for in its entirety at estimated fair value with changes in estimated fair value recorded in earnings;

• the terms of the embedded derivative are not clearly and closely related to the economic characteristics of the host contract; and

• a separate instrument with the same terms as the embedded derivative would qualify as a derivative instrument.

Such embedded derivatives are carried on the balance sheet at estimated fair value with the host contract and changes in their estimated fair value are generally reported in net derivative gains (losses), except for those in policyholder benefits and claims related to ceded reinsurance of GMIB. If the Company is unable to properly identify and measure an embedded derivative for separation from its host contract, the entire contract is carried on the balance sheet at estimated fair value, with changes in estimated fair value recognized in the current period in net investment gains (losses) or net investment income. Additionally, the Company may elect to carry an entire contract on the balance sheet at estimated fair value, with changes in estimated fair value recognized in the current period in net investment gains (losses) or net investment income if that contract contains an embedded derivative that requires bifurcation. At inception, the Company attributes to the embedded derivative a portion of the projected future guarantee fees to be collected from the policyholder equal to the present value of projected future guaranteed benefits. Any additional fees represent “excess” fees and are reported in universal life and investment-type product policy fees.

See Note 7 for information about the fair value hierarchy for derivatives.

Derivative Strategies

The Company is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. The Company uses a variety of strategies to manage these risks, including the use of derivatives.

Derivatives are financial instruments with values derived from interest rates, foreign currency exchange rates, credit spreads and/or other financial indices. Derivatives may be exchange-traded or contracted in the over-the-counter (“OTC”) market. Certain of the Company’s OTC derivatives are cleared and settled through central clearing counterparties (“OTC-cleared”), while others are bilateral contracts between two counterparties (“OTC-bilateral”). The types of derivatives the Company uses include swaps, forwards, futures and option contracts. To a lesser extent, the Company uses credit default swaps and structured interest rate swaps to synthetically replicate investment risks and returns which are not readily available in the cash market.

Interest Rate Derivatives

The Company uses a variety of interest rate derivatives to reduce its exposure to changes in interest rates, including interest rate swaps, caps, floors, swaptions, futures and forwards.

Interest rate swaps are used by the Company primarily to reduce market risks from changes in interest rates and to alter interest rate exposure arising from mismatches between assets and liabilities (duration mismatches). In an interest rate swap, the Company agrees with another party to exchange, at specified intervals, the difference between fixed rate and floating rate interest amounts as calculated by reference to an agreed notional amount. The Company utilizes interest rate swaps in fair value, cash flow and non-qualifying hedging relationships.

The Company uses structured interest rate swaps to synthetically create investments that are either more expensive to acquire or otherwise unavailable in the cash markets. These transactions are a combination of a derivative and a cash instrument such as a U.S. Treasury, agency, or other fixed maturity security. Structured interest rate swaps are included in interest rate swaps and are not designated as hedging instruments.



Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 6. Derivatives (continued)

The Company purchases interest rate caps and floors primarily to protect its floating rate liabilities against rises in interest rates above a specified level, and against interest rate exposure arising from mismatches between assets and liabilities, as well as to protect its minimum rate guarantee liabilities against declines in interest rates below a specified level, respectively. In certain instances, the Company locks in the economic impact of existing purchased caps and floors by entering into offsetting written caps and floors. The Company utilizes interest rate caps and floors in non-qualifying hedging relationships.

In exchange-traded interest rate (Treasury and swap) futures transactions, the Company agrees to purchase or sell a specified number of contracts, the value of which is determined by the different classes of interest rate securities, and to post variation margin on a daily basis in an amount equal to the difference in the daily market values of those contracts. The Company enters into exchange-traded futures with regulated futures commission merchants that are members of the exchange. Exchange-traded interest rate (Treasury and swap) futures are used primarily to hedge mismatches between the duration of assets in a portfolio and the duration of liabilities supported by those assets, to hedge against changes in value of securities the Company owns or anticipates acquiring, to hedge against changes in interest rates on anticipated liability issuances by replicating Treasury or swap curve performance, and to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. The Company utilizes exchange-traded interest rate futures in non-qualifying hedging relationships.

Swaptions are used by the Company to hedge interest rate risk associated with the Company's long-term liabilities and invested assets. A swaption is an option to enter into a swap with a forward starting effective date. In certain instances, the Company locks in the economic impact of existing purchased swaptions by entering into offsetting written swaptions. The Company pays a premium for purchased swaptions and receives a premium for written swaptions. The Company utilizes swaptions in non-qualifying hedging relationships. Swaptions are included in interest rate options. The Company enters into interest rate forwards to buy and sell securities. The price is agreed upon at the time of the contract and payment for such a contract is made at a specified future date. The Company utilizes interest rate forwards in cash flow hedging relationships.

## Foreign Currency Exchange Rate Derivatives

The Company uses foreign currency exchange rate derivatives, including foreign currency swaps, foreign currency forwards, currency options and exchange-traded currency futures, to reduce the risk from fluctuations in foreign currency exchange rates associated with its assets and liabilities denominated in foreign currencies. The Company also uses foreign currency derivatives to hedge the foreign currency exchange rate risk associated with certain of its net investments in foreign operations.

In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company utilizes foreign currency swaps in fair value, cash flow and non-qualifying hedging relationships.

In a foreign currency forward transaction, the Company agrees with another party to deliver a specified amount of an identified currency at a specified future date. The price is agreed upon at the time of the contract and payment for such a contract is made at the specified future date. The Company utilizes foreign currency forwards in fair value, net investment in foreign operations and non-qualifying hedging relationships.

The Company enters into currency options that give it the right, but not the obligation, to sell the foreign currency amount in exchange for a functional currency amount within a limited time at a contracted price. The contracts may also be net settled in cash, based on differentials in the foreign currency exchange rate and the strike price. The Company uses currency options to hedge against the foreign currency exposure inherent in certain of its variable annuity products. The Company also uses currency options as an economic hedge of foreign currency exposure related to the Company's international subsidiaries. The Company utilizes currency options in net investment in foreign operations and non-qualifying hedging relationships.

To a lesser extent, the Company uses exchange-traded currency futures to hedge currency mismatches between assets and liabilities, and to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. The Company utilizes exchange-traded currency futures in non-qualifying hedging relationships.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

## 6. Derivatives (continued)

## Credit Derivatives

The Company enters into purchased credit default swaps to hedge against credit-related changes in the value of its investments. In a credit default swap transaction, the Company agrees with another party to pay, at specified intervals, a premium to hedge credit risk. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the delivery of par quantities of the referenced investment equal to the specified swap notional amount in exchange for the payment of cash amounts by the counterparty equal to the par value of the investment surrendered. Credit events vary by type of issuer but typically include bankruptcy, failure to pay debt obligations, repudiation, moratorium, involuntary restructuring or governmental intervention. In each case, payout on a credit default swap is triggered only after the Credit Derivatives Determinations Committee of the International Swaps and Derivatives Association, Inc. (“ISDA”) deems that a credit event has occurred. The Company utilizes credit default swaps in non-qualifying hedging relationships.

The Company enters into written credit default swaps to synthetically create credit investments that are either more expensive to acquire or otherwise unavailable in the cash markets. These transactions are a combination of a derivative and one or more cash instruments, such as U.S. Treasury securities, agency securities or other fixed maturity securities. These credit default swaps are not designated as hedging instruments.

The Company also enters into certain purchased and written credit default swaps held in relation to trading portfolios for the purpose of generating profits on short-term differences in price. These credit default swaps are not designated as hedging instruments.

The Company enters into forwards to lock in the price to be paid for forward purchases of certain securities. The price is agreed upon at the time of the contract and payment for the contract is made at a specified future date. When the primary purpose of entering into these transactions is to hedge against the risk of changes in purchase price due to changes in credit spreads, the Company designates these transactions as credit forwards. The Company utilizes credit forwards in cash flow hedging relationships.

## Equity Derivatives

The Company uses a variety of equity derivatives to reduce its exposure to equity market risk, including equity index options, equity variance swaps, exchange-traded equity futures and total rate of return swaps (“TRRs”).

Equity index options are used by the Company primarily to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. To hedge against adverse changes in equity indices, the Company enters into contracts to sell the equity index within a limited time at a contracted price. The contracts will be net settled in cash based on differentials in the indices at the time of exercise and the strike price. Certain of these contracts may also contain settlement provisions linked to interest rates. In certain instances, the Company may enter into a combination of transactions to hedge adverse changes in equity indices within a pre-determined range through the purchase and sale of options. The Company utilizes equity index options in non-qualifying hedging relationships. Equity variance swaps are used by the Company primarily to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. In an equity variance swap, the Company agrees with another party to exchange amounts in the future, based on changes in equity volatility over a defined period. The Company utilizes equity variance swaps in non-qualifying hedging relationships.

In exchange-traded equity futures transactions, the Company agrees to purchase or sell a specified number of contracts, the value of which is determined by the different classes of equity securities, and to post variation margin on a daily basis in an amount equal to the difference in the daily market values of those contracts. The Company enters into exchange-traded futures with regulated futures commission merchants that are members of the exchange.

Exchange-traded equity futures are used primarily to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. The Company utilizes exchange-traded equity futures in non-qualifying hedging relationships.

TRRs are swaps whereby the Company agrees with another party to exchange, at specified intervals, the difference between the economic risk and reward of an asset or a market index and the London Interbank Offered Rate (“LIBOR”),



calculated by reference to an agreed notional amount. No cash is exchanged at the outset of the contract. Cash is paid and received over the life of the contract based on the terms of the swap. The Company uses TRRs to hedge its equity market guarantees in certain of its insurance products. TRRs can be used as hedges or to synthetically create investments. The Company utilizes TRRs in non-qualifying hedging relationships.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (Continued)

6. Derivatives (continued)

Primary Risks Managed by Derivatives

The following table presents the gross notional amount, estimated fair value and primary underlying risk exposure of the Company's derivatives, excluding embedded derivatives, held at:

Primary Underlying Risk Exposure	September 30, 2015		December 31, 2014	
	Gross Notional Amount	Estimated Fair Value	Gross Notional Amount	Estimated Fair Value
		Assets	Liabilities	Assets